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Chapter 1 
IMMUNOLOGICAL PHENOMENA AFTER CARDIAC VALVE 
TRANSPLANTATION: REVIEW OF THE LITERATURE 
This chapter is based on: 
"The activation of the immune system by human cardiac valve allografts", accepted for 
publication in: 
Cardiac reconstructions with allograft valves, 2nd edition, Hopkins RA, Ed, Springer-
Veriag, New York. 
Franciska M.E. Hoekstra, Christiaan J. Knoop, Ad J.J.C. Bogers and Willem Weimar. 
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1.1 Introduction. 
Allogeneic transplantation has become an accepted method for the 
replacement of diseased organs and tissues. The concept of cardiac valve 
transplantation for the replacement of semilunar valves was introduced by 
Lam et al in 1952'. In about 1960 the first human cardiac valve allografts 
were implanted,,3, Human donor valves have become a good alternative for 
other valve substitutes (porcine valve prostheses and mechanical valves) 
because of their superior hemodynamic performance and the absence of 
post-operative thrombosis and thromboembolism. Further, these valves are 
relatively resistant to endocarditis and recipients of human donor valves do 
not require anticoagulant therapy. 
At this moment, the valve allografts are stored at heart valve banks. In 
1995, 68 heart valve banks were known world-wide'. Before the introduction 
of cryopreservation techniques, human valve allografts were stored at 4"C in 
a nutrient medium containing an antibiotic solution, with a maximum storage 
time of 6 weeks5". These antibiotic-sterilized, "fresh wet-stored" allografts 
showed a better medium-term (7-10 years) clinical performance than 
glutaraldehyde-treated human valves"'. Alternative storage techniques 
(freeze-drying, irradiation) resulted in a shorter long-term graft survival 
compared to mechanical valves"" and a higher incidence of cusp rupture". 
The introduction of cryopreservation procedures offered long-term storage 
and improved the availability of the valves, 
In The Netherlands, cryopreserved human valves are stored at the Heart 
Valve Bank, Thorax Center, University Hospital Rotterdam-Dijkzigt. The 
aortic and pulmonary valves are obtained from heart beating donors or from 
non-heart beating donors within 24 hours after death. At this moment, 
contraindications for valve donation are donor age older than 55 years, 
sepsis, congenital heart anomalies and heart valve diseases, myocarditis, 
hypertrophic obstructive cardiomyopathy or previous cardiac surgery, 
Marfan's disease and malignancies. Patients with a positive screeningstest 
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for Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus 
(HIV) or lues are also excluded". World-wide there is no agreement on the 
minimum acceptable age of valve donation'. The hearts are explanted under 
aseptical conditions by a surgical team of Bio Implant Services (BIS). 
Thereafter, the valves are prepared at the Heart Valve Bank under sterile 
conditions. Before the cryopreservation procedure, the allografts are 
incubated into a low concentration antibiotic solution for 24 hours at 4°C. 
Dimethylsulfoxide (DMSO) is used to reduce the damage caused by 
freezing. Thawing occurs according to the standard thawing protocol of the 
Heart Valve Bank at the day of valve implantation. 
1.2 Clinical valve allograft survival. 
In general, the precision of valve allograft insertion has been regarded as 
the most accurate predicting factor for early and long-term graft survival 14 . 
Factors which are significantly associated with valve allograft failure are 
younger age of the recipient at operation, low weight of the recipient, young 
donor age, small graft size and a cryopreservation time less than 24 
hours15.". However, the variability in patient age, surgical techniques, 
perioperative mortality and preservation techniques interfere with the 
possibility to make a valid comparison between different follow-up studies. 
Long-term follow-up studies after implantation of cryopreserved valves show 
good clinical results, especially in adult recipients 17.18. Nevertheless, valve 
deterioration resulting from an intrinsic abnormality of the graft (e.g. leaflet 
tear, calcification, stenosis or stent creep) is frequently reported. This 
structural valve failure, which is not related to technical factors as sizing 
and surgical procedures, infection or thrombosis as determined by 
reoperation, is frequently seen 19. Structural valve deterioration does not 
necessarily lead to valve dysfunction20.22 • However, some studies give rise to 
concern about the incidence of graft failure, especially early valve allograft 
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which is frequently observed in young recipients23~2s Freedom from 
reoperation of cryopreserved valves placed into the right ventricular outflow 
tract in children only ranges from 55-80% at 4 to 6 years after 
implantation 15,16,26~2'. Baskett et al examined the function of cryopreserved 
pulmonary valve allografts echocardiographically in 44 children (mean age at 
implantation: 6.2 years, range: 3 days to 20.2 years). After 50 months, 
freedom from echocardiographic graft failure was 44%. In this study, graft 
failure was defined as more than 50 mmHg pulmonary regurgitation'5. In our 
center, 189 patients (mean age 16 years, range: 2 weeks - 54 years) with 
an allograft in the right ventricular outflow tract were followed for 2.5 years 
(mean, range: 4 weeks to 9 years). In this study, the patient survival at 5 
years was 91% and freedom from structural valve failure was 83%'6. Many 
authors suggested that structural valve failure could have an immunological 
basis, because valve donor and acceptor are not matched for ABO blood 
group antigens or the transplantation antigens, the Major Histocompatibility 
Complex (MHC) antigens, while immunosuppressive therapy is not routinely 
administered to valve recipients. The antigenicity of cardiac valve allografts 
has been a matter of debate since their introduction for clinical use. Fresh 
and cryopreserved valves have classically been regarded as tissues with low 
antigenicity because of the relatively good medium-time clinical performance 
without immunosuppression. 
In this chapter, the immunological aspects of cardiac valve transplantation in 
animal studies (sensitization of the recipients, histological and 
immunohistochemical findings of explanted valve allografts in vivo) are 
discussed. Further, results of studies directed at the immunogenicity of 
human cardiac valve allografts, the effect of the ABO blood group 
compatibility between valve donor and recipient on valve allograft survival 
and some aspects of immunomodulation and immunosuppression are 
expounded. 
12 
1.3 Immunogenicity of allogeneic valves in animal studies. 
To analyse the antigenicity of fresh and cryopreserved allogeneic cardiac 
valves in vivo, various animal models have been used. These studies mainly 
aimed at sensitization of recipients, histological signs of rejection after 
implantation of allogeneic valves and on the possible correlation between 
immunological activity against the graft and valve insufficiency. 
Sensitization of valve recipients was examined by Mohri et al. They showed 
that allogeneic skin grafts were rapidly rejected when dogs were sensitized 
by subcutaneous implantation of a valve of the same donor". In contrast, 
when a valve instead of a skingraft was transplanted in the orthotopic 
position in these sensitized animals, no acute rejection was observed. 
Histological examination showed only few polymorphonuclear leukocytes 
and mononuclear cells in an intact valve stroma. No significant differences 
were found in the functional durability of orthotopically transplanted leaflets 
in either sensitized or nonsensitized dogs. However, plasma cells and 
lymphocytes infiltrating the allogeneic implants were Observed more than 2 
months after transplantation. The authors suggested that this late cellular 
rejection could be the result of the low antigenicity of the aortic valve. This 
conclusion is not in line with their findings that these valves are able to 
sensitize their experimental animals as they showed by the rapid rejection of 
skin grafts. An alternative explanation could be that these transplanted 
valves are not instantly recognized, not even by a sensitized immune 
system, suggesting that the implantation procedure temporarily affected the 
antigenicity of the valve. The relative lack in immune response is, however, 
not an uniform finding. 
Baue and collegues examined the immunologic response to heterotopic 
fresh aortic valve transplants in non sensitized calves and animals 
presensitized with donor skin30. Destruction of the allogeneic valves after 7 
days of transplantation was found in all instances. No histological 
differences in the explanted valve allografts were found between the 
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presensitized and nonsensitized animals. In this study, the histological 
findings were comparable to those of rejecting organ transplants, although 
the acute rejection process did not result in dysfunction of the transplanted 
valves. 
Buch et al examined histological differences between transplanted 
allogeneic and autologous valve allografts in dogs after various months after 
transplantation31 . In the allogeneic explanted valves, structural alterations 
were observed already 5 days after implantation. Absence of endothelium 
and a zone of acellularity just below the surface of the valves was observed, 
while autologous grafts retained the normal endothelial lining. Three months, 
6 months and 1 year after implantation, both homologous and autologous 
valves were moderately thickened due to hypercellularity. The explanted 
grafts showed fibroblast hyperplasia and areas of acellularity, but infiltrates 
were not detected. Despite the histological evidence of valve damage, these 
valves retained their function during this experimental study31. 
In a study on rats, Thiede et al examined the level of sensitization after 
transplantation of one versus two allogene,c valve leaflets. The valves were 
implanted intravascularly and the time to skin rejection was measured. One 
heart valve leaflet caused strong sensitization, resulting in accelerated skin 
rejection. There was no statistically significant difference in the moment of 
rejection between rats that received one or two valve leaflets, showing that 
the quantity of valve antigen was not able to either enhance or suppress the 
antigeneic process. In this report, the degree of sensitization varied 
significantly according to the degree of histoincompatibility32, which was also 
observed by Khatib et al in a comparable study33. Lupinetti et al examined 
the effect of immunological different rat strains on aortic valve allograft 
calcification". These authors were not able to demonstrate a correlation 
between the degree of histoincompatibility and calcification on scanning 
electron microscopical findings, although syngeneic valves showed less 
calcified areas than allogeneic valves in this model". Immunogenetic factors 
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were also of importance in a study by Gonzalez-Lavin et ai, who showed 
that transplantation of valves between genetically related dog combinations 
was associated with significantly less degenerative changes compared to 
histological findings in valves transplanted between genetically different 
dogs35• 
Zhao et al examined the immune response to MHC antigens after 
implantation of an allogeneic valve in different rat strains'S. The proliferative 
response of acceptor lymphocytes against donor spleen cells was measured 
before and after implantation of the allogeneic valve using mixed lymphocyte 
cultures. The authors demonstrated a donor-specific stimulation one month 
after implantation. The same group also observed an increase of donor-
specific cytotoxic T-Iymphocyte frequencies in a limiting dilution assay with 
splenocytes, accompanied by an increase in the level of anti-donor 
antibodies36 . 
In conclusion, these animal studies show that implantation of allogeneic 
valves is followed by a specific donor-directed immunological response. 
Histological signs of acute and chronic rejection, especially in the allogeneic 
grafts are generally observed, although these findings do not always 
correlate with valve dysfunction. Autologous valves show less signs of 
inflammation than allogeneic valves, and the degree of the immune 
response is related to the degree of histoincompatibility in some animal 
models presented. These results suggest that matching for MHC antigens 
can result in a decreased immune response against the donor valve. 
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1.4 Immunogenicity of human valves. 
Target antigens: ABO blood group and Major Histocompatibility 
Complex antigens. 
ABO blood group antigens could playa role in valve allograft rejection. The 
effect of compatibility for ABO blood group antigens between valve donor 
and acceptor on graft survival has sparsely been reported in the literature, 
mainly in retrospective studies. Some investigators have carried out ABO 
matching and even recommend ABO matching""?"'. In other studies, a 
relation of ABO blood group incompatibility and valve allograft failure could 
not be found15,38"o The relation between valve insufficiency and blood group 
incompatibility approached significance (p=O,05) in the echocardiographic 
follow-up study of young children by Baskett et al 15, In contrast, Balch and 
collegues could not demonstrate a correlation between ABO compatibility 
and long-term valve allograft survival41 • In this study, the majority of the 
patients with valve failure (130/188 patients) were ABO compatible. 
Regardless of this finding, the authors mentioned the presence of denuded 
endothelium, fibrin deposits, calcification and mononuclear infiltrates in 
unsuccessful aortic valve transplants, suggesting a role for other antigens 
than the ABO blood group system in evoking an immune response. The cell 
surface antigens coded by the Major Histocompatibility Complex (MHC) are 
obvious candidates. The presence of these so-called transplantation 
antigens is a prerequisite for the initiation of an immune response against 
foreign tissue. In humans, the Major Histocompatibility Complex molecules 
are called the Human Leucocyte Antigens (HLA), The HLA class I molecules 
(HLA -A, -B and -C) are membrane glycoproteins, which can be expressed 
by many nucleated cells. HLA class II molecules (HLA -DR, -DQ, and -DP) 
are present on antigen presenting cells (dendritic cells, Langerhans' cells), 
B-Iymphocytes and activated T-lymphocytes42. In valve transplantation, the 
viability of fibroblasts and endothelial cells is considered to be an important 
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factor contributing to immunostimulation, because both fibroblasts and 
endothelial cells cultured from valve allografts have shown to be able to 
express Human Leucocyte Antigens (HLA) class I and class II antigens. 
Salomon et al examined the expression of HLA class II antigens on 
fibroblasts cultured from cryopreserved aortic valves after incubation with 
Interferon-gamma43 . The authors observed an upregulation of class II 
antigens on the majority of fibroblasts. Yacoub et al also examined the 
presence of HLA-antigens in different components of human cardiac valves. 
The valve allografts were studied by staining with monoclonal antibodies and 
the influence of sterilization procedures was investigated44 . Before storage, 
valve allografts showed weak staining for class I antigens on endothelial 
cells, which gradually disappeared within 48 hours during storage in 
Hartmann's solution. Within the matrix, class I positive leucocytes were 
observed which also disappeared within 48 hours. Class II staining of 
endothelium was negative both before and after storage, but positive for 
cells just below the endothelium, possibly representing the presence of 
leucocytes or dendritic cells. As endothelial cells form the first barrier 
between the allo-reactive immune system and the donor valve, these cells 
could play an important role in the initiation of the immune response against 
the donor valve. To analyze the immunogenicity of valve endothelium in 
vitro, Simon et al cultured endothelial cells from fresh valve leaflets45 , 
according to the isolation method of Johnson and Fass46 . Mixed cell cultures 
with valve endothelium as stimulator and lymphocytes as responder cells 
resulted in high proliferative responses. A very potent antigen presenting cell 
which could be present in a valve before implantation is the dendritic cell. 
This cell expresses various surface markers including HLA class II antigens, 
complement receptors and adhesion molecules. These cells are difficult to 
identify, because many other cells like fibroblasts, lymphocytes and 
macrophages stain positive after incubation with these markers. The nerve 
tissue protein S-100 stains a wide group of dendritic cells, but does not stain 
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fibroblasts, lymphocytes and macrophages47,4'. Bobryshev and Lord used 
this marker to identify dendritic cells into the arterial intima, because the 
intima is not innervated and is not supposed to contain other S-100 positive 
cells, They indeed detected areas of the arterial wall with S-100 positive 
cells". Because human valve allografts also contain an aortic or pulmonary 
root, dendritic cells could playa role in the antigen presentation after valve 
allograft transplantation. Schoen et al examined cryopreserved valve 
allografts which had to be explanted because of growth-related conduit or 
valve stenosis. They concluded that the function of cryopreserved valves is 
not related to the presence of viable cells, but to preserved collagen50 
Immunohistochemical studies of these explants showed that inflammatory 
cells, primarily T-Iymphocytes, were present in only one valve (out of 20 
valves examined), while viable fibroblasts or endothelial cells could not be 
detected. 
Immunological response. 
By staining with monoclonal antibodies, Yankah et al identified activated 
complement (C3C) and immunoglobulins on the surface of explanted 
allogeneic valves 4 weeks after implantation,s,51. In these studies, the 
immunological findings were not related to valve failure. In a comparable 
study by Lupinetti et al more or less the same results were obtained5'. To 
follow the immunological process after allogeneic valve implantation, 
cytoimmunological monitoring has been used by Schutz et al53 . This group 
examined 16 patients who had received ABO compatible (n=9) or ABO 
incompatible (n=7) cryopreserved aortic valves. An immunological reaction 
could be detected in all patients 5 days after implantation. The increased 
activation index spontaneously disappeared after 7 days without the use of 
immunosuppressive drugs, but in the ABO compatible group a prolonged 
activation was observed. Echocardiography as postoperative function control 
3 months after implantation showed hemodynamically irrelevant valve 
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insufficiency in both groups. The authors conclude that transplantation of 
cryopreserved allogeneic valves leads to an immunological reaction in the 
early postoperative course due to T-cell activation which is reversible, and 
that ABO incompatibility does not affect the echocardiographic outcome after 
3 months. Although in our opinion cytoimmunological monitoring is a method 
which is too nonspecific to diagnose rejection after organ transplantation54 , it 
may certainly reflect nonspecific immunological reactivity in peripheral blood 
after valve transplantation. 
The detection of allo-antibodies after implantation of valve allografts could 
give information about the presence of immunogeneic Human Leucocyte 
Antigens in the graft. Davies et al examined serum of patients who received 
a freeze-dried allogeneic valve, but they failed to detect antibodies55 . 
1.5 Modulation of valve antigenicity. 
Studies in animals and humans after cardiac valve implantation which are 
focussed on signs of rejection show different results. An explanation for 
these different results could be the varying preservation methods, which can 
lead to a change in the cellular composition of graft, resulting in modification 
of the antigeneic load. A reduction of the antigenicity of the transplant could 
lead to a less aggressive immune response of the acceptor. Reducing the 
number of cells expressing transplantation antigens, as mentioned on the 
preceding pages, is an option, provided that the function of the valve leaflets 
remains unaffected. Preservation methods can therefore be considered as 
forms of immunomodulation. It has been reported by EI Khatib et al that 
fresh aortic valve allografts contain more viable endothelial cells than 
allografts stored at 4'C in an antibiotic solution, leading to the loss of 
anligeneic load'"' Transplantation of allogeneic valves between rat strains 
resulted in a shorter time to skin graft rejection when fresh valves were 
transplanted, compared to rats that received an allograft preserved for 21 
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days in a nutrient medium'6. Lang et al detected viable endothelial cells on 
cryopreserved valves (and no viable fibroblasts)57, while van de Kamp et al 
reported the presence of viable fibroblasts and an intact structure of 
collagen fibrills after sterilization and controlled freezing of aortic valves58 . 
Brockbank et al confirmed an enhanced fibroblast viability after 
cryopreservation and storage at -135'C up to 2 years by measuring the 
glycine uptake59 , but valves stored at -80'C showed loss of fibroblast viability 
after 1-6 weeks59 . The group of Lupinetti used immunofluorescence staining 
technics to show that endothelial cells were present on the surface of the 
valve leaflets from 16% of 131 cryopreserved aortic valve allografts6o 
Yankah et al also demonstrated the presence of viable endothelial cells on 
the valve surface after cryopreservation, while on fresh sterilized valves 
these cells were absent61. These studies show that the presence of 
endothelium on cryopreserved valves may vary. To our opinion, this can be 
explained by the use of different freezing technics and antibiotic sterilization 
procedures. Nevertheless, endothelial cells could be important initiators of 
the allogeneic immune response, and in studies on the immunogenicity of 
vascular endothelium, these cells even have shown to be a major target of 
cell mediated immune-injury62-65. Moreover, both cytotoxic T-cells and allo-
antibodies specifically directed at endothelial cell surface molecules have 
also been detected in explanted rejected organs66-68 . 
Long-term follow-up studies of patients in the clinic show a marked 
improvement with the transplantation of cryopreserved valve allografts 
compared to fresh valves17 , suggesting that the cellular composition, the 
collagen structure or antigenicity of valve allografts is altered by 
cryopreservation. Cochran used Fisher rats to study the effect of 
cryopreservation on the antigen expression of aortic allografts69 . Allogeneic 
aortic valves were implanted subcutaneously and the time of skin graft 
rejection (first and second set reaction) was compared between recipients of 
fresh and cryopreserved valves. No statistical difference was found between 
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fresh and cryopreserved valves for first and second set rejection 
phenomena, indicating no effect of cryopreservation. 
Calhoun examined the difference between survival of fresh and 
cryopreserved venous allografts in genetically characterized dogs70 . In 
contrast to Fisher, he detected early deterioration of the intima of 
cryopreserved venous grafts while the fresh venous transplants were 
histologically normal. It remained unclear why cryopreservation was 
associated with early thrombosis and transplant failure in this study. 
Nevertheless, cryopreservation and/or thawing could damage the intima of 
the venous allografts, leading to thrombotic complications. 
Jonas et al compared hemodynamic, angiografic and histological findings in 
a long-term sheep model after implantation of a cryopreserved versus an 
antibiotic sterilized aortic valve allograft". The authors found no significant 
difference in transconduit gradient or histological findings 9 months after 
transplantation, but calcification was prominent within the conduit wall of all 
animals. 
Modulation of alloreactivity by phenotypic manipu lation of donor endothelium 
has been performed on heart allografts in rats". Therefore, host 
endothelium was isolated and perfused into donor allografts. Allografts 
pretreated with host-endothelium survived for 12 days, while untreated heart 
allografts survived 7 days. This method could become an alternative method 
to reduce the immunogenicity of valve allografts, because endothelial cells 
can be easily isolated" and valve allografts could remain ex vivo for more 
extended periods than heart transplants to allow attachment of the donor 
endothelium on the graft. Another alternative could be the pretreatment of 
allografts with cyclosporine, which has been earlier performed on venous 
allografts in dogs. This treatment resulted in an improved survival of the 
graft and also in less degenerative changes observed by scanning electron 
microscopic examination74 . 
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1.6 Immunosuppression. 
Immunosuppressive drugs are not routinely administered to recipients of 
human cardiac valves, in contrast to patients who receive allogeneic bone 
marrow or an organ transplantation. Further, valve donor and recipient are 
not matched for MHC antigens. The effect of immunusuppression on 
histological findings of valve rejection could be compared in patients who 
received heart transplants (with immunosuppressive therapy) and patients 
who received valve allografts (no immunosuppression). Schoen et al and the 
group of Melo found as most striking factor that there was a marked 
decrease in cellularity (fibroblasts) in the valve replacement group compared 
to the heart transplantation group, and T-cells were especially present in 
valve allografts but not into the valve leaflets of heart transplant 
recipients5D•75•77 • 
Clarke et al described a possible beneficial effect of antiinflammatory agents 
on allograft survival in young children. These few children, who only 
received anti-imflammatory drugs during the early postoperative period did 
not require reoperation 23 . One child was treated with low-dose cyclosporin 
and underwent reoperation 4 months later. The explanted allograft of this 
child remained free from calcification in contrast to comparable explanted 
valves, suggesting a protecting effect of cyclosporin on allograft 
degeneration21 . 
Cyclosporin is a highly potent immunosuppressive drug, that has thus far 
only been used in individual cases in the clinic for the indication of valve 
replacement. The general opinion of the use of this drug after valve 
implantation is to use it with caution because of its serious side-effects. 
There are no reports in the literature of controlled follow-up studies of 
patients with an allogeneic valve treated with cyclosporin or other 
immunosuppressive drugs and the effect on valve function. However, Augelli 
et al examined dogs receiving venous allografts with or without cyclosporin 
treatment. Dogs treated with cyclosporin showed improved graft survival 
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compared to dogs that received no immunosuppression78. Yankah et al 
treated Lewis rats which received an allogeneic valve with a short course of 
cyciosporin A (10 mg/kg daily for 14 days). This resulted in the prevention of 
early valve degeneration observed on histological examination in the 
cyclosporin-treated rats, compared to rats with an allograft which were not 
treated with cyciosporin A". 
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Chapter 2 
AIM OF THE THESIS 
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Rejection is a phenomenon commonly observed after allogeneic organ or 
bone marrow transplantation. The destruction caused by the immunologic 
activation may eventually lead to graft failure 1.2 Transplantation antigens 
play an important role in the initiation of a donor-specific rejection process, 
which consists of complex interactions of immune-competent cells of the 
recipient with Major Histocompatibility Complex (MHC) molecules of the 
donor, resulting in the activation of the cellular and humoral immune 
response. The cellular immune response is initiated by the presentation of 
donor antigens by antigen-presenting cells in the graft to immune competent 
cells of the recipient. This can lead to the activation of T -lymphocytes of the 
graft acceptor. Activated T-Iymphocytes bear an Interleukin-2 receptor and 
can produce Interleukin-1 and other Iymphokines to stimulate T-cell 
proliferation'-'- In the graft, this leads to upregulation of adhesion molecules 
and MHC antigens, which are rapidly recognized and destroyed by allo-
reactive T -lymphocytes. The antibodies formed after initiation of the humoral 
immune response after bone marrow or organ transplantation, can be 
directed against MHC antigens or blood group antigens6.'. In human valve 
allograft transplantation, the grafts are randomly allocated to the recipients. 
Because of the variability of the Human Leucocyte Antigen (HLA) system, it 
is unlikely that valve recipients are compatible with donor transplantation 
antigens. Many experimental animal studies already showed findings of 
rejection with deterioration of the valve leaflets in allogeneic transplanted 
valves. These data produced in animal models can not necessarily be 
extended to human valve transplantation. The contribution of immunological 
damage to the graft and subsequently valve insufficiency still remains 
unclear. Many authors believed that human valves only bear a low 
antigeneic load, but this assumption has not been scientifically tested. 
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In our center, histological examination of valve allografts explanted because 
of valve insufficiency, showed infiltrates consisting of lymphocytes and a 
strongly reduced amount of fibroblasts which are normally present in a heart 
valve leaflet. These degenerative changes are frequently observed; 
degeneration still remains the most frequent cause of allogeneic valve 
failure'. Therefore we hypothesized that allogeneic valves evoke a donor-
specific immune response, leading to destruction of viable cells in the graft, 
which may eventually lead to graft failure (valve insufficiency in the clinical 
setting). The aim of this thesis is to investigate the cellular and humoral allo-
reactive immune response induced by fresh and cryopreserved human 
cardiac valve allografts. Therefore, we made use of laboratory assays which 
were earlier used for the evaluation of the alloreactive immune response 
after heart transplantation. The studies concerning the cellular immune 
response were performed at the department of Internal Medicine I 
(Transplantation Laboratory), University Hospital Rotterdam-Oijkzigt. 
Antibody detection took place at the department Immunohematology and 
Blood Bank, University Medical Center Leiden. 
In chapter 3, we describe the results of in vitro studies. The effect of fresh 
valve pieces on the Iymphoproliferative capacity of responder lymphocytes 
mismatched for HLA -A, -B, and -DR with the valve donor, was tested in a 
lymphocyte stimUlation essay. Further, we tried to culture endothelial cells 
from fresh valve leaflets, which were subsequently tested in a mixed cell 
culture for their stimulatory effect on Iymphoproliferation. We also show the 
effect of HLA -DR matching and cryopreservation on Iymphoproliferation in 
lymphocyte stimulation tests. 
In chapter 4, we examine the phenotype and donor-specific cytotoxic 
capacity of graft infiltrating cells. If in vivo activated T-Iymphocytes, baring a 
T-cell receptor, are present in the explanted graft, these cells can be 
cultured by incubation with Interleukin-2 in an ex vivo model. Clones of the 
cells obtained can be phenotyped and tested for allo-reactivity. 
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In the next chapter the allo-reactive antibody response directed against HLA 
class I and class II antigens in patients who received a cryopreserved valve 
allograft during the first year after transplantation is described. 
In chapter 6, the results of an immunohistochemical study directed at the 
cellular composition of fresh and cryopreserved valve allografts, the 
presence of antigen presenting cells and the expression of transplantation 
antigens and some immunological activation markers are shown. 
Finally, the results and conclusions of the previous chapters are summarized 
in chapter 7. 
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Abstract 
Both fresh and cryopreserved human cardiac valve allografts are 
transplanted without matching for blood group or Human Leucocyte Antigens 
(HLA) with their recipient, and without the usual immunosuppressive therapy 
administered to patients after organ transplantation. Calcification occurs in 
almost all transplanted valves, and in children even acute valve failure is 
frequently seen. We hypothesized that failure of the human valve allografts 
could have an immunological basis. This hypothesis was tested in a functio-
nal way by performing lymphocyte stimulation assays using fresh and 
cryopreserved valve pieces and endothelial cells derived from valve leaflets 
as stimulator. Human peripheral blood lymphocytes, both matched and 
mismatched for H LA antigens were used as responder cells. The tritiated 
thymidine incorporation into the lymphocytes was measyred after 7 days. 
The results were expressed as stimulation index (SI). Fresh valve pieces 
induced a significantly higher SI (median: 9, range 4-117), compared to the 
cryopreserved (median: 2, range 0-9, p=0.002, Wilcoxon). The SI was 
significantly reduced when lymphocytes matched for HLA -DR with the valve 
pieces were used (median: 1, range 0-5) versus the HLA -DR mismatched 
combination (median: 4, range 2-117, p=O.006, Wilcoxon). Valve leaflet 
derived endothelial cells were able to induce a median SI of 8 (range 3-15) 
when incubated with lymphocytes mismatched for HLA -A, -B and -DR. In 
conclusion, stimulation of immune competent cells in vitro is induced both by 
fresh and cryopreserved human valve pieces and by endothelial cells 
derived from fresh valve leaflets. The immune response can be reduced by 
using cryopreserved valves or by matching between valve donor and 
responder lymphocytes for HLA -DR. Viable endothelial cells, present on 
fresh but not on cryopreserved valves could play a major role in the high 
immunogenicity of fresh valves. The cellular allogeneic response in vitro 
could be an explanation for valve allograft degeneration observed in the 
clinic. 
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Introduction 
Fresh human cardiac valve allografts as well as cryopreserved valves are 
used for the reconstruction of congenital and acquired valve diseases. The 
good results during the first few years 1 after transplantation of these valves 
without HLA-matching between donor and recipient did not induce a 
discussion about the effect of histoincompatibility on the functioning of these 
valves. Although acute valve failure is frequently encountered, especially in 
children, now long-term follow-up studies show that valve calcification 
resulting in valve insufficiency is also commonly seen'·'. Apart from technical 
problems, immunological phenomena might result in valve destruction and 
this is even a likely explanation as valve donor and recipient differ in 
histocompatibilty antigens. Endothelial cells are the barrier between the 
allograft valve and the acceptor and these cells are known to evoke an 
immune reaction4.'. Therefore, the stimulatory capacity of endothelium 
derived from fresh valve allografts was tested in a mixed endothelium-
Iymphocyle reaction. We also investigated whether fresh and cryopreserved 
human cardiac valve pieces are able to evoke an immunologic reaction by 
testing their capacity to induce a proliferative response of immune-
competent cells in vitro. As responder cells, peripheral blood lymphocytes 
mismatched for HLA -A, -8 and -DR were used. The proliferative response 
of HLA -DR matched lymphocytes was also tested. 
Material and methods 
Valve allografts 
Human pulmonary and aortic valve allografts were prepared under sterile 
conditions from hearts of heartbeating or non-heartbeating donors within 24 
hours after death"- For the present study, aortic and pulmonary valve were 
studied that were not accepted for transplantation, mostly because of techni-
cal reasons. The valve allografts were all placed for 24 hours at 4°C in a low 
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concentration antibiotic solution, containing flucytosin 0.03 mg/ml, 
vancomycin 0.012 mg/ml, amikacin 0.012 mg/ml, ciprofloxan 0.003 mg/ml 
and metronidazol 0.012 mg/ml in medium 199 (Gibco, Paisley, Scotland). 
Two fresh valve leaflets were prepared. The third valve leaflet connected to 
the arterial trunk was cryopreserved according to the standard 
cryopreservation protocol (_1°C per minute) in medium 199 containing 10% 
DMSO. The cryopreserved leaflet was quickly thawed after 12-24 hours 
(standard thawing protocol). One fresh leaflet and a cryopreserved leaflet 
derived from the same valve were cut into pieces with a 2 millimeter 
diameter biopsy punch (Stiefel Laboratories LTD). These pieces were each 
placed in a well of a 96-well culture cluster (Costar, Cambridge,MA) with 
culture medium, consisting of 10% heat-inactivated human serum, 4 mM L-
glutamine, 100 IU/ml penicillin and 100 pg/ml streptomycin in RPMI 1640 
Dutch Modification (Gibco, Paisley, Scotland). 
Isolation of endothelial cells 
The third leaflet was used to isolate endothelial cells according to the 
method of Johnson and Fass'. Therefore, the fresh leaflet was rinsed gently 
in medium 199 after the antibiotic bath, then it was placed for five minutes in 
a 1 mg/ml collagenase solution (Collagenase A, Boehringer, Mannheim) in 
HBSS (Gibco, Paisley, Scotland) at 37'C. It was rinsed gently in HBSS 
without calcium and magnesium (Gibco) and thereafter placed in 1 ml 
endothelial cell culture medium (RPMI 1640: medium 199 1:1 (Gibco) and 
30% heat-inactivated human serum) with 50 pg/ml Endothelial Cell Growth 
Supplement (Collaborative Research Incorporated, Bedford, MA) and 50 
pg/ml Heparin (Sigma, St Louis, MO). After 1 minute gentle shaking by 
hand, the leaflet was removed and the culture medium containing the 
endothelial cells was put into one well of a 24-well Prima ria dish (Becton & 
Dickinson, Mountain View, CAl. At confluence the endothelial cells were 
passaged after trypsinisation in trypsin EDTA (0.05% I 0.02%). Six sets of 
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endothelial cells were derived from six different valves. The purity of the cell 
lines was assessed by double staining with FITC-Iabelled Ulex Europaeus 
lectin and the monoclonal antibody EN4 (Sanbio, Uden, The Netherlands) in 
combination with anti-mouse kappa-PE (Becton & Dickinson) and 
subsequently analyzed on a FACScan flow cytometer (Becton & Dickinson). 
Lymphocyte stimulation assay 
Peripheral blood lymphocytes, 1.10' per well, matched or mismatched for 
HLA-DR were incubated in the presence of irradiated (30Gy) fresh or 
cryopreserved valve pieces or endothelial cells in a total volume of 200 III at 
37'C in a humidified atmosphere of 5% CO2 in air. The [3H]thymidine 
incorporation into the lymphocytes was measured after 7 days incubation. 
First the valve pieces were removed from the wells and then 0,5 uCi 
[3H]thymidine was added to each well. After 8 hours incubation in a 
humidified atmosphere, the lymphocytes were harvested on glass fiber 
filters. The proliferation assay using endothelial cells as stimulator was 
performed as described above in the presence of 1.10' irradiated endothelial 
cells per well. For positive control third party Epstein Bar Virus transformed 
B-Iymphoblastoid cell lines were used as stimulator while autologous 
irradiated lymphocytes served as negative controls. The [3H]thymidine 
incorporation into endothelial cells was nihil. The 3H thymidine incorporation 
was measured in the Beta Plate Counter (LKB, Sweden). The tests were 
performed in tenfold. Results were expressed as stimulation index (SI) : the 
cpm incorporated in lymphocytes incubated with valve pieces or in 
endothelial cells, divided by the cpm incorporated in negative controls. 
Results 
Significant proliferative responses were found in all instances where fresh 
valve pieces, cryopreserved valve pieces or endothelial cells were used as 
stimulator incubated with HLA -A, -B and -DR mismatched lymphocytes. 
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Fresh valve pieces induced a significantly higher 81 compared to 
cryopreserved valves: median 9 (range: 4-117) for fresh versus 2 (range 0-
9) for cryopreserved valves, p=0.002, Wilcoxon (figure 1). 
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Figure 1. Median stimulation index of lymphocytes incubated with fresh versus 
cryopreserved valve pieces. All lymphocytes were mismatched for HLA-A, -8 and -DR 
with the valve leaflets. Each line connects the median stimulation index of fresh and 
cryopreserved valve leaflets derived from the same valve. 
Endothelial cell cultures were obtained in almost all instances (14/15) when 
fresh leaflets were used, while cryopreserved valves did not yield viable 
endothelial cell cultures in any of the 5 tested instances. Endothelial cells 
induced a median 81 of 8, range: 3-11 (figure 2). Compared to the 81 of the 
fresh valve pieces from the same valve, endothelial cells induced a median 
81 of 8 (range 3-11) versus 10 (median, range 5-35) for fresh valve pieces. 
In contrast, cryopreserved leaflets induced less proliferation than endothelial 
cells derived from the same valve, with a median 81 of 2 (range 0-9). 
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STIMULATION INDEX 
A B c o E F 
Figure 2. Stimulation index induced by valve endothelial cells. Bars represent different 
endothelial cell lines derived from six different valve leaflets. 
A very weak proliferative capacity was found for HLA-DR matched 
lymphocytes incubated with either fresh (n=3) or cryopreserved (n=4) valves; 
the median SI of HLA -A, -8 and -DR mismatched lymphocytes was 4 
(range 2-117) versus 1 (range 0-5) for HLA-DR matched lymphocytes 
(p=0.006, Wilcoxon, figure 3), resulting in a median decrease of 90% due to 
HLA-DR matching. 
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Figure 3. Median stimulation index of lymphocytes mismatched versus matched for HLA-
DR with the valve donor. In all cases, lymphocytes were mismatched for HLA-A and -S 
with the valve pieces. Incubation with fresh ( .. ) or cryopreserved ( + ) valve pieces. 
Discussion 
Transplantation of allogeneic organs between histoincompatible individuals 
will give rise to an immune response. The importance of histocompatibility 
was earlier suggested by Yankah et alB" who described infiltrates consisting 
of lymphocytes in transplanted allogeneic human valves. An immunologic 
reaction, especially the cellular reaction by human T-Iymphocytes against 
HLA-antigens can result in destruction and dysfunction of the graft. In this 
study, we found that human cardiac valves evoke a proliferative response of 
HLA -A, -S and -DR mismatched lymphocytes, and that matching of HLA-DR 
between valve donor and responder lymphocytes resulted in a significantly 
lower stimulation of Iymphoproliferation, Therefore, we suggest that an 
immunologic reaction is involved in the failure of human valve allografts, as 
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earlier described in animal studies1O,11,12,13, In the present study we report 
that valve derived endothelial cells alone have the potential to activate 
immune competent cells, This may be the result of upregulation of HLA-
antigens or other allo-antigens on their cell surface'4 Further studies using 
endothelium-lymphocyte reactions could clarify the importance of HLA class 
I and class II. In our experiment endothelial cells could not be propagated 
from cryopreserved valves, suggesting the absence of viable endothelium 
after cryopreservation, Histological examination of cryopreserved valves in 
our institution did not show the presence of endothelial cells on the surface 
of valve leaflets, This was earlier reported by Lupinetti15, In parallel to these 
results we found a lower proliferation of immune competent cells when 
incubated with cryopreserved valve pieces compared to the fresh leaflets, 
In conclusion, we suggest that destruction of transplanted human cardiac 
valves may be the result of a cellular immune response, that 
cryopreservation or matching for HLA -DR is associated with less immuno-
stimulation and that endothelial cells present on the surface of fresh 
allografts could be responsible for the initiation of the immunologic reaction, 
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Abstract 
We studied the presence of donor-specific T-Iymphocytes in explanted 
human cardiac valve allografts in vivo. From five out of seven explants 
lymphocyte cultures were propagated in an Interleukin-2 conditioned 
medium. Phenotyping revealed the presence of T-cell receptors in more 
than 95% of the lymphocytes obtained in each culture. Donor-specific 
cytotoxicity was demonstrated in three patients with known HLA-status of 
the donor. In one patient, cytotoxicity was directed against HLA class I only 
and against class I and/or class II in the others. These results indicate that 
donor-specific cellular reactivity can be induced by transplantation of human 
cardiac valve allografts. 
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Introduction 
Human cardiac valves are transplanted without the immunosuppressive 
therapy normally given to recipients of vascularized organ transplants, 
because it is supposed that antigenicity does not playa major role in graft 
survival. However, early valve failure is not uncommon, and especially in 
children other than technical causes are suggested to playa role " In animal 
models the antigenicity of valve allografts was illustrated earlier"', 
Sensitization of the recipient against allogeneic valves was revealed by the 
rejection of donor specific skin transplants4 and by the measurement of allo-
antibodies', Recently, a donor-specific cellular immune response in vivo has 
been demonstrated in rat spleen cells after valve allograft transplantation', 
Studies on the antigenicity of human valve allografts have been limited to 
sparse descriptions of histological findings of infiltrates in explanted valves', 
In addition, we showed stimulation of immune competent cells by human 
valve leaflets in vitro" 
In the present study, we examined the immune response after 
transplantation of human cardiac valves in an ex vivo model. We cultured 
graft infiltrating lymphocytes from explanted human cardiac donor valves, 
and tested them for donor-specific reactivity, 
Material and Methods 
Patients. 
Valve recipients were between 8 months and 60 years of age at the time of 
transplantation, Valve allografts (4 aortic and 3 pulmonary) were obtained 
from heart beating (n=6) and non-heart beating (n=1, patient 1) donors after 
preparation and cryopreservation according to the Standard Preparation 
Protocol of the Heart Valve Bank Rotterdam', Three valves were placed in 
the aortic position and four were used to reconstruct the right ventricular 
outflow tract. The interval between transplantation and explantation, the 
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causes of valve failure leading to explantation, and HLA-type of the valve 
donor are shown in Table 1. Four valves were explanted between 19 and 84 
months after transplantation because of structural valve failure, which refers 
to changes intrinsic to the valve, causing stenosis or regurgitation 10 One 
valve was ex planted because of nonstructural valve deterioration 6 months 
after transplantation. Nonstructural dysfunction refers to any abnormality 
resulting in stenosis or regurgitation that is not caused by intrinsic changes 
of the valve. Two allografts were explanted for not valve related reasons (in 
one case the allograft was obtained at autopsy after the recipient had died 
in a car accident, and in the other case it was obtained 4,5 hours after 
transplantation for technical reasons because of take down of intracardiac 
repair). HLA-typing of the valve donor was performed on spleen cells or 
peripheral blood mononuclear cells, isolated on Ficoll-paque (d=1.077) 
density gradient centrifugation (Pharmacia, Uppsala, Sweden) separation. 
HLA class I antigens were typed according to the standard NIH 
Iymphocytotoxicity assay. Highly selected antisera were used for HLA-DR 
typing ". The HLA-type of the valve recipients was not available. The 
Medical Ethical Committee of the University Hospital Rotterdam approved 
the studies. 
Table 1. Patient characteristics. 
(age) HLA-type donor graftwsulVival mode of failure 
1 (25) unknown 84 months structural deterioration 
2 (0,7) A 1A2 6768 DR2DR3 46 months structural 
3 (35) A2A32 651 DR11DR13 6 months non-structural 
4 (8) A2 662 DR2DR4 30 months structural 
5 (60) A2A30 651662 DR4 5 months patient death' 
6 (20) A2 67660 DR2DR4 19 months structural 
7 (4) A1A32 65168 DR17DR12 4.5 hours patient death' 
'Patient death not related to valve allograft failure. Age: years. 
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Culture method 
From each explanted valve, the valve leaflets were cut into 2 millimeter 
diameter pieces with a biopsy punch (Stiefel Laboratories LTD, UK). These 
pieces were placed in 96 well roundbottom tissue culture plates (Costar 
3799, Cambridge, MA) with 200 pi Culture Medium (CM), which consisted of 
RPMI 1640 Dutch Modification (Gibco, Paisley, Scotland) supplemented with 
10% heat-inactivated human serum, 10% vol/vol lectin-free Lymphocult-T-LF 
(Biotest GmbH, Dreiech, Germany), as exogenous source of IL-2, 4mM L-
glutamine, 100 IU/ml penicillin and 100 pg/ml streptomycin. Irradiated (40 
Gy) autologous or third party peripheral blood mononuclear cells (1.105 cells 
per well) served as feeder. Peripheral blood mononuclear cells (PBMC) 
were isolated on Ficoll-paque. The cultures were grown at 37"C in a 
humidified atmosphere with 5% CO, and every 2 to 3 days half the medium 
was replaced by fresh CM. When growth of lymphocytes was observed, the 
pieces were removed and the contents of several wells were pooled. When 
sufficient cell density was reached, the contents of the wells were 
transferred to more wells. 
Phenotypic analysis 
T-cell lines were analyzed by three-color flow cytometry for the expression 
of cell surface antigens after staining with monoclonal antibodies. As pan T-
cell marker, WT31, recognizing T-cell receptor alpha/beta (TCR alpha/beta) 
was used, and anti-leu3 (CD4) and anti-leu2 (CD8) were used as T-cell 
subset markers. Anti-leu19 (CD56) and anti-leu11 (CD16) were used as 
markers for natural killer (NK) cells. 11 F2 was used as marker for TCR 
gamma/delta expression. Antibodies were directly conjugated to FITC, PE or 
PERCP (Becton & Dickinson, Mountain View, CAl. 5.104 cells were 
incubated with fluoresceinated monoclonal antibodies for 30 minutes at room 
temperature. Cells were subsequently washed in PBS and 5000 cells were 
analyzed in a lymphocyte gate on a FACScan (Becton & Dickinson, 
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Mountain View, CAl. Lymphocyte gate was set on Forward and Sideward 
light scatter, while cell debris was gated out by a threshold on Forward light 
scatter. 
Cell-mediated cytotoxicity 
A standard 4 hours 51Cr release assay12 was performed to measure the 
cytotoxic capacity of the cultures against a panel of target cells, sharing one 
or more H LA antigens with the valve donor. Three types of target cells were 
used: PHA-blasts as target for activity against HLA class I antigens, Epstein 
Bar Virus transformed B-cell lines as targets for class I and class II antigens 
and the K562 and DAUDI cell lines as control for NK cell and Iymphokine 
activated killer cell (LAK) activity. 
3.10' 51Cr-labelled target cells/well were placed in 96-well round bottomed 
culture plates, and effector cells were added at an effector target ratio from 
1:1 to 20:1. The plates were centrifuged (60g, 1 minute) and incubated for 4 
hours at 37°C in a humidified atmosphere with 5% CO,. Supernatants were 
collected with a Skatron harvesting system (Skatron-AS, Lierse, Norway) 
and counted in a gamma counter for 3 minutes. Percentage lysis was 
calculated according to the formula: 
experimental release - spontaneous release 
% lysis = X 100 
maximal release - spontaneous release 
Maximal release was determined in four-fold from a Triton X 100 (5% v/v 
solution in 0.01 M TRIS-buffer) lysate of the target cells. Spontaneous 
release was determined in four-fold by incubation of target cells in medium 
(RPMI-1640 Dutch Modification, supplemented with 1 % heat inactivated 
serum). Cultures were considered cytolytic when the experimental lysis 
percentage exceeded 10% at an effector:target ratio of 20:1 or greater and 
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the slope of the graph was positive". 
Numerical results are presented as median with range. Clinical and allograft 
characteristics were compared with the Wilcoxon test or Student's t-test 
where approprate. A p-value smaller than 0.05 was considered to be 
significant 
Results 
Although several explants showed macroscopic and microscopic signs of 
calcification, lymphocyte cultures were obtained from five out of seven 
available human cardiac donor valves from the valve leaflet and/or the 
vessel wall (Table 2). These cultures all contained 95% or more T-cell 
receptor bearing cells. The median percentage of CD8 positive lymphocytes 
in these cultures was 40% (range: 27 to 83%), while the median percentage 
of CD4 positive lymphocytes was 58% (range: 16 to 97%) (Table 2). One 
lymphocyte culture was obtained from a valve of which the HLA status of 
the donor was not available and could not be tested for donor specificity in a 
CML One allograft had only been transplanted for 4,5 hours and served as 
control for the test system. This valve explant indeed did not generate a 
lymphocyte culture. Finally, six cultures derived from four remainingexplants 
were tested in a CML against a panel of target cells sharing one or more 
HLA antigens with the valve donor. More than 60% lysis of cells sharing 
HLA antigens with the valve donor was observed in four cultures, derived 
from three explants (patient 3, 4 and 5, figure 1-4). No correlation was found 
between explants showing donor-specific lysis, age at time of implantation, 
graft survival or mode of failure. In patient 2 the culture consisted of CD4 
positive cells only and showed no cytotoxic reactivity. As shown in Table 2, 
in two cases lymphocyte cultures were generated from both valve leaflet and 
vessel wall (patient 3 and 4). The phenotype of the two cultures derived 
from the allograft and vessel wall in patient 3 were identical, while the 
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phenotype of these two cultures differed in patient 4. 
As negative controls, third party celis (sharing no HLA-antigens with the 
donor) were used in the cytotoxicity test These celis were not lysed and in 
addition both N K and LAK activity also remained within relatively low ranges 
(figures 1-4). According to these results, cytotoxicity of the recipient 
lymphocytes was documented against H LA class I antigens of the donor in 
one patient (patient 4), while in the other two patients cytotoxicity might be 
directed against HLA class I and/or class II antigens. 
Table 2. Lymphocyte culture characteristics. 
Cell growth Phenotype cultures Donor-specific lysis 
pat leaflet vessel leaflet vessel leaflet vessel 
+ ND 52% WT31/CD4 ND ND 
46% WT31/CD8 
2 ND + 97%WT31/CD4 
3 + + 58% WT31/CD4 58%WT31/CD4 + + 
40% WT31/CD8 39%WT31/CD8 
4 + + 95% WT31/CD4 57% WT31/CD4 + 
27% WT31/CD8 
15% TCR gamma/delta 
5 + ND 16% WT31/CD4 + 
83% WT31/CD8 
6 ND 
7 ND 
ND: not done. TCR: T-cell receptor. pat: patient 
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Figures 1-4. Donor-specific Iympholysis by valve allograft infiltrating cells. 
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Figure 1. Patient 3. Lymphocyte cultures derived from the vessel wall. HLA antigens that 
are matched with valve donor antigens are underlined in the key. LAK: Iymphokine-
activated killer cell. 
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Figure 2. Patient 3. Lymphocyte cultures derived from the valve leaflet. HLA- antigens 
that are matched with valve donor antigens are underlined in the key. LAK: Iymphokine-
activated killer cell. 
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Figure 3. Patient 4. Lymphocyte cultures derived from the vessel wall. HLA-antigens that 
are matched with valve donor antigens are underlined in the key. LAK: Iymphokine-
activated killer cell. 
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Figure 4. Patient 5. Lymphocyte cultures derived from the valve leaflet. HLA-antigens that 
are matched with valve donor antigens are underlined in the key. LAK: Iymphokine-
activated killer cell. 
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Discussion 
From earlier in vitro and experimental animal studies it was clear that 
cardiac valve allografts are able to stimulate the immune system2-6 . In the 
present study, we showed for the first time in a functional way that after 
valve allograft transplantation, cytotoxic lymphocytes are generated in at 
least some allografts (5 out of 6 in our study) that are specifically directed 
against donor antigens. We cultured alloreactive T-cells in IL-2 conditioned 
medium, in which only activated IL-2 receptor bearing lymphocytes are 
supposed to grow. Similar immunological methods 
applied to characterize graft infiltrating cells 
have already been 
after solid organ 
transplantation 13-15. In these reports a correlation between the presence of 
donor-specific cytotoxic T-cells in the graft and rejection was described, 
confirming the clinical relevance of these studies. 
The small number of our present series cardiac valve allografts prohibits us 
to make a correlation between in vivo data and patient characteristics. 
Nevertheless, our study unequivocally demonstrates lymphocytes infiltrating 
the transplanted valve, which may lead to immunological inflammation, 
potentially resulting in tissue damage and thus allograft dysfunction. 
Endothelial cells probably play a key role in this proces. Previously we 
showed that valve endothelial cells are able to induce Iymphoproliferation, 
while heart endothelial cells can also be targets for cytotoxic 
lymphocytes 16."- Although valve allograft dysfunction not necessarily results 
in cardiac failure, a significant number of valve replacements is necessary, 
especially in young reCipients '. 
In conclusion, our study shows that donor directed immune mechanisms are 
among the factors possibly leading to tissue damage and valve allograft 
failure. Prospective immunologic monitoring is needed to assess the relative 
importance of this particular factor. Manipulation of the allograft to reduce 
the antigenicity should be considered, and indeed, cryopreservation is 
associated with a reduced immunogenicity compared to fresh valve 
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allografts'. In the present study we found activity against HLA class I and 
class II antigens, and we already showed in vitro evidence for the 
importance of HLA class II matching' which could be considered in 
individual patients in case of second valve replacements and in children with 
their high risk of valve failure. Alternatively, low-dose immunosuppression 
could be given to high risk patients 
" 
but only for a short while because 
complications of long-term immunosuppression may not outweigh its 
benefits at the moment. 
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Chapter 5 
DONOR-SPECIFIC ANTI-HUMAN LEUCOCYTE ANTIGEN 
CLASS I AND CLASS II ANTIBODIES AFTER 
IMPLANTATION OF CARDIAC VALVE ALLOGRAFTS 
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Abstract 
Background. The kinetics of Panel Reactive Antibodies (PRA) and 
incidence of antibodies directed against Human Leucocyte Antigen (HLA) 
class I and class II were studied in patients who received a cryopreserved 
cardiac valve allograft 
Methods. A complement-dependent microlymphocytotoxicity test was used 
to determine the percentage PRA and the specificity of the anti-HLA class I 
antibodies. Anti-HLA class II antibodies were measured by two color 
fluorescence assays. 
Results. The PRA became positive in 25/32 (78%) of the recipients between 
1 and 16 months after implantation. In blood samples taken on the day of 
implantation, no antibodies could be detected. In 26 patients the HLA-type of 
the valve donor was available. In 21/23 patients of which the donor HLA-
type was available and with a follow-up period of more than one month, 
antibodies were present In 17 of these 21 patients (81%) antibodies were 
specifically directed against HLA class I of the donor. Antibodies against 
HLA class II antigens were detected in 11/30 (37%) patients. In 9/11 (82%) 
cases these antibodies were donor-specific. The induction of antibodies 
against donor HLA class II antigens suggests that intact HLA class II 
antigens are expressed by viable cells within the graft. Oithiothreitol (OTT) 
analysis showed that the antibodies were of the Immunoglobulin G (lgG) 
type. Apparently, the HLA class II antigens are expressed in an immunoge-
neic way as activation of specific T-Helper cells is essential for the switch 
from IgM to IgG antibodies. 
Conclusions. Allogeneic valve transplantation is associated with the 
production of donor-specific anti-HLA class I and class II antibodies which 
could contribute to graft failure. This possibly detrimental effect might be 
prevented by cross matching in sensitized patients. 
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Introduction 
Human cardiac valve allografts have been used for years for the 
reconstruction of cardiovascular anomalies. In adult recipients good clinical 
results have been reported in a number of series 1.', although the durability of 
the grafts is limited. In young recipients early valve failure is more 
frequent'·4.'. In our center, the 10-years graft-survival of allografts implanted 
into the right ventricular outflow tract was 70% at a mean patient age of 22 
years'. Although valve failure is related to different extrinsic factors including 
sizing, surgical technics and preservation methods, structural valve failure, 
due to intrinsic abnormalities of the valve leaflets? may have an immunologic 
basis. Allo-antigens, which stimulate the immune system of the recipient and 
are responsible for rejection in organ transplantations could also be present 
on valve allografts. Indeed, after preservation procedures like 
cryopreservation or fresh storage, valve allografts generally contain viable 
cells'" capable of expressing HLA class I and class II antigens'°·". While the 
leaflet matrix is important for the long-term function of the valve leaflets, and 
fibroblasts are responsible for the maintenance of this matrix12, these viable 
cells could be responsible for the initiation of the activation of the immune 
system of valve recipients. In animal studies the antigenic properties of 
allogeneic valves have been clearly demonstrated". The immunogenicity of 
fresh and cryopreserved human valves in vitro is described in Chapter 3 of 
this thesis. High proliferative responses were found in lymphocyte 
stimulation assays when responder lymphocytes were mismatched for HLA -
A, -8 and -DR with the valve donors 14 Endothelial cells cultured from fresh 
valves also induced significant proliferation of mismatched responder 
lymphocytes15. In Chapter 4 we showed that graft-infiltrating cells could be 
cultured from explanted allografts and their cytotoxicity was shown to be 
donor-specific in a cell-mediated Iympholysis assay'"' The cultures obtained 
were cytotoxic against donor H LA class I and/or class II antigens in 5/6 
explants16. These data show that the cellular immune system is activated by 
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allogeneic valve transplantation. Antibodies directed against donor Major 
Histocompatibility Complex (MHC) antigens have been detected on 
explanted valve allografts 1? Because of the presence of HLA class II 
antigens on cryopreserved valves and the cytotoxic activity of graft-
infiltrating cells against these antigens, we supposed that a humoral 
response against HLA class II antigens could also be present. Hogan et al 
detected anti-HLA class II antibodies in 4/11 patients who received a 
cryopreserved valve allograft". However, cardiac valve preparation methods 
vary in surgical centers, for example different concentrations of antibiotics 
in the nutrient medium, duration of the antibiotic bath, and varying ischemia 
times, which could lead to a different antigenic load of the valves before 
implantation. We studied the incidence of anti-HLA class I and class II 
antibodies in peripheral blood samples of valve recipients in our center 
during the first year after transplantation. We also established the kinetics of 
the formation of panel reactive antibodies (PRA). 
Material and method 
Patients 
Heparin-treated blood samples were taken at varying times after 
implantation from 32 patients (21 men and 11 woman) who received a 
cryopreserved pulmonary or aortic valve allograft. The allografts had been 
implanted for various indications including endocarditis and congenital 
anomalies. The median age of the recipients was 41 years (range: 3 to 69 
years). Two patients received a second allogeneic valve. Five patients were 
treated with steroids peri operatively e.g. because of chronic obstructive 
pulmonary disease and sarcoidose. The Medical Ethical Committee of the 
University Hospital Rotterdam and the Medical Faculty of the Erasmus 
University Rotterdam had approved the study and patients gave informed 
consent before participation. 
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Valve allografts 
Aortic and pulmonary roots were obtained from heart beating and non-heart 
beating donors within 24 hours after death. Preparation took place under 
sterile conditions according to standard operation procedures. Subsequently 
the grafts were sterilized for 24 hours at 4'C in Medium 199 (Bio-Whittaker, 
Alkmaar, The Netherlands) containing a low concentration antibiotic solution: 
vancomycin 0.012 mg/ml, flucytosin 0.03 mg/ml, amikacin 0.012 mg/ml, 
metronidazol 0.012 mg/ml and ciprofloxacin 0.003 mg/ml. Thereafter they 
were cryopreserved according to a standard cryopreservation protocol (-1'C 
per minute) in Medium 199 containing 10% dimethyl sulfoxide (DMSO), and 
stored in the vapour phase of liquid nitrogen (-160 to -180'C) at the Heart 
Valve Bank in Rotterdam, The Netherlands. Just before implantation, the 
selected valves were thawed in a 37°C bath the DMSO was removed by 
stepwise dilution in Medium 199. 
Blood sampling 
Blood samples were taken once after transplantation in 18/32 patients. From 
14/32 patients 2 or more samples were collected, one sample immediately 
before valve implantation (negative controls) and thereafter between 1 week 
and 3 months, 3 to 6 months, 6 to 12 months or longer than one year after 
implantation. 
Antibody screening 
PRA and Anti-HLA class I antibody screening 
Screening of patient plasma was performed by the standard National 
Institutes of Health (NIH) complement-dependent microlymphocytotoxicity 
test (LCT) against a panel of 50 selected donors carrying the majority of the 
serologically defined HLA-A and HLA-B specificities 19. A positive reaction 
was defined as greater than 30% dead cells per well. Results were 
expressed as percentage panel reactive antibodies (PRA): the number of 
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positive donors divided by the number of donors tested. The screening was 
considered positive when the PRA was equal to or more than 9%. 
Anti-HLA class /I antibody screening 
Platelet absorbed patient sera were tested for H LA class II specific antibody 
reactivity in a two color fluorescence assay20. The specificity of the 
antibodies was determined on the basis of their reactivity against a panel of 
60 HLA-DR and HLA-DQ typed donors. 
Oithiothreitol (OTT) analysis 
OTT was used for the immunoglobulin (Ig) class determination21 . A negative 
antibody screening test after OTT reduction is indicative for the presence of 
IgM antibodies only, and the detection of antibodies despite OTT treatment 
is an indication for IgG antibodies (with or without IgM antibodies). 
Results 
Incidence of panel reactive antibodies. 
Panel reactive antibodies (PRA) against HLA class I were detected in 25/32 
(78%) of the recipients. Eight patient samples showed no significant PRA, 
but in 5 out of these patients the samples were taken within 4 weeks after 
implantation, which could be too early to detect antibodies. Antibodies 
against HLA class II antigens were detected in 11/30 (37%) valve recipients. 
Determination of the antibodies in the presence of OTT showed that these 
antibodies were IgG antibodies in all cases. 
Kinetic aspects. 
The follow-up group consisted of 10 men and 4 woman. Five patients 
received more than one blood transfusion. Four patients had received an 
aortic allograft and the remaining patients received a pulmonary graft. In the 
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14 blood samples taken directly before implantation, no antibodies could be 
detected. The production of antibodies started between 1 to 3 months after 
transplantation in 6 patients and in 4 patients antibodies were present 
between 3 to 6 months after transplantation, but from these patients no 
blood sample was available for the period 0 to 3 months. The PRA remained 
positive for more than 6 months in 8/14 recipients (figure 1). 
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Figure 1. Follow-up of the Panel Reactive Antibodies. The PRA of both the cross 
sectional group and the follow-up group are used for this figure. 
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Specificity of the antibodies. 
The HLA-type of the donor was available in 26 patients. In 3 of them 
bloodsamples were taken within the first month after transplantation. In 
21/23 remaining patients (91 %) with a known HLA-type of the valve donor, 
anti-HLA class I antibodies were detected. Out of these 21 patients, 17 
patients (81%) had specific antibodies against HLA class I of the valve 
donor (table 1). No correlation could be found between the presence of 
panel reactive antibodies and peri operative blood transfusions. 6/17 patients 
with donor-specific allo-antibodies against HLA class I were woman, of 
which one had been pregnant. The presence of anti-HLA class II antibodies 
was measured in 30 patients. In 11/30 (37%) patients antibodies against 
HLA class II could be detected. Of one patient with anti-HLA class II antibo-
dies, the HLA class II-type of the donor was not available. In 9 (82%) 
patients the antibodies against HLA class II were donor-specific (table 1). All 
patients with antibodies against HLA class II antigens had also antibodies 
against H LA class I antigens. 
70 
Table 1. Specificity of the antibodies of patients of which the HLA-type of 
the valve donor was available and with a follow-up period of more than one 
month. 
Patient 
(sex/age) 
1 (1/29) 
2(m/57) 
3(1164) 
4(m/64) 
5(1/26) 
6(m/37) 
7(m/50) 
8(m/59) 
9(m/28) 
10(m/26) 
11 (1/64) 
12(m/65) 
13(m/31) 
14(m/51) 
15(m/49) 
16(m/42) 
17(m/26) 
18(1139) 
19(1/66) 
20(m/57) 
21 (m/28) 
22(1/41 ) 
23(m/3) 
time 
after Tx 
13 
13 
13 
11 
12 
11 
7 
8,5 
4 
4,5 
7 
1,5 
3 
4,5 
4 
13 
6 
13 
13 
5 
4,5 
6 
9 
6T PRA(%) 
50 
27 
+ 59 
+ 0 
77 
+ 73 
77 
+ 50 
0 
38 
86 
+ 73 
73 
40 
27 
+ 73 
82 
59 
+ 60 
57 
40 
50 
+ 91 
Anti-HLA 
class I ab 
67627 
A9 
A2 
A19 
67 
A267 
6w4 
A11 67 
A1 A3 67 
6w4 
A2 612 640 
A9 
617 
A2A9A11 
A1 A2 840 
A2 
812(44) 813 640 
A1A2A11 
812613 
A3612 
A1 A24 
Anti-HLA 
class II ab 
DR3 
DR1 
DR7 
DR8 
DQ3 
DR51 
DR8 DR52 DQ2 
DR6(14) 
DR52 
DR53 
Donor-specific antibodies are underlined. Tx, transplantation; PRA, panel reactive 
antibodies; f,female; m, male; ab, antibodies; age, expressed in years at time of transplan-
tation. 
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Discussion 
The implantation of cardiac valve allografts was found to be associated with 
the production of donor-specific anti-HLA class I and anti-HLA class II 
antibodies in the majority of the recipients. These results support the 
assumption that cryopreserved human cardiac valves contain viable cells 
which are able to express HLA class I and class II antigens. The 
immunogenicity of these antigens is reflected by the high PRA detected and 
the specificity of these antibodies for donor allo-antigens. Antibody 
production in valve recipients started approximately 4 weeks after 
transplantation. In patients who received blood transfusions, antibodies are 
generally detected already after 2 weeks after administration. The delay of 
antibody production in valve transplantation could be caused by a later 
onset of the presentation of HLA class I and class II antigens, possibly 
because of a recovery phase of viable cells after thawing and implantation. 
As compared to the humoral response after the implantation of homovital 
valves, antibiotic sterilization for 24 hours and the cryopreservation 
procedure in our center did not lead to lower percentages panel reactive 
antibodies after 3 months to 1 year after transplantation. 
The finding that the antibodies were IgG antibodies suggests the 
involvement of T-Helper lymphocytes in the immune response, because 
these cells are necessary for the switch of the production of IgM antibodies 
to IgG antibodies. This activation of T-Helper cells is in agreement with 
earlier results of the detection of donor specific cytotoxic T -lymphocytes into 
explanted valve allografts, which also implies a role of T-Helper cells 1". For 
the initiation of an antibody-response directed against class II antigens, 
direct presentation of intact donor class II antigens is necessary. 
Presentation of HLA class II antigens into valve allografts could be attributed 
to dendritic cells, endothelial cells and fibroblasts. The presence of dendritic 
cells in the valve leaflet has not been confirmed in the literature, but 
Bobryshev et al reported dendritic cells in aortic vessel walls2'. The vessel 
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wall represents an important component of the valve allograft. Endothelial 
cells are not consistently present on cryopreserved valves. Lupinetti et al 
showed that cryopreservation of human donor valves is associated with loss 
of endothelial cells". In our center histological examination showed that only 
a few endothelial cells were present on cryopreserved valves before 
implantation (unpublished data). Viable fibroblasts are found in the majority 
of cryopreserved valve leaflets before implantation", but it is not clear how 
long these cells survive after transplantation. Neves et al detected 
fibroblasts in explanted valve allografts on histological examination24. They 
also compared the number of fibroblasts in heart valve recipients and 
patients with a donor heart. In the heart transplantation group, which is 
treated with immunosuppressive drugs, the number of fibroblasts was 
normal. In contrast, the valve recipients who do not receive 
immunosuppression, the number of fibroblasts was strongly reduced. The 
reduction of the amount of fibroblasts in transplanted valve allografts could 
be caused by the cryopreservation procedure, but could also be due to 
immunological destruction'4 Schoen et al described 20 explanted 
cryopreserved valve allografts, which were morphologically non-viable and 
unlikely to have active metabolic functions25. 
In conclusion, these data show that viable cells capable of the expression of 
HLA class I and class II antigens are present in cryopreserved human valve 
allografts. Allo-antibodies induced by the graft could damage transplanted 
tissue and therefore may contribute to graft dysfunction. We recommend to 
perform prospective cross matching to prevent acute antibody-mediated 
rejections in high-risk patients: i.e. young recipients, in need of a 
retransplantation. 
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Chapter 6 
THE CELLULAR BASIS OF THE DONOR-SPECIFIC 
IMMUNE RESPONSE AGAINST HUMAN HEART VALVE 
ALLOGRAFTS AND THE PRESENCE OF MASKED 
ACTIVATED ENDOTHELIAL CELLS 
Submitted. 
Christiaan J. Knoop, Franciska ME Hoekstra, Frieda van der Ham, Zohara Aghai, Claes 
Wassenaar, Pieter E. Zondervan, Carla C. Baan, Ad J.J.C. Bogers and Willem Weimar. 
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Abstract 
Objective: In vitro and in vivo studies on both animals and humans have 
shown that cardiac valve allografts evoke donor-specific humoral and cellular 
immune responses which may contribute to valve dysfunction. Therefore, we 
examined the cells within the valves, which might be responsible for the 
initiation of these immune responses. 
Methods: Human valves were analysed by immunohistochemical techniques 
using monoclonal antibodies against cell surface determinants. From each 
valve, fresh and cryopreserved leaflets and vascular walls were studied. 
Results: No B-Iymphocytes (CD20) and hardly any CD56 positive Natural 
Killer cells were found. A scattered pattern of macrophages was seen 
throughout the leaflet and the vascular wall. Many S-100 positive cells of 
neural origin were found in the valve leaflets. However, no double staining 
S-100/CD45 antigen presenting cells were present. Although no CD31 
positive endothelial cell lining was present on the valve surface, ICAM-1 and 
HLA class II expressing endothelial cells were detected in the vasa vasorum. 
Groups of CD3 positive T-Iymphocytes were found on the ventricular part of 
the leaflets and in the tunica adventitia. No differences were observed 
between fresh and cryopreserved valves in the presence or the distribution 
of the cell types investigated. 
Conclusion: These data indicate that fresh and cryopreserved valves 
contain activated ICAM-1 positive endothelial cells, which also express HLA 
class II and thus may serve as targets for a donor-specific immune 
responses. Moreover, these cells could also be responsible for the initiation 
of the immune response because of their non-professional antigen 
presenting properties. 
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introduction 
For the reconstruction of ventricular outflow tracts, cryopreserved human 
cardiac valve allografts have been used with good clinical results 1-'. In our 
centre the overall 5 years graft-survival is 78% in patients with an allograft 
implanted into the right ventricular outflow tract'. Although degenerative 
changes have been observed in many explanted valve allografts, especially 
in young recipients5,6", the relation between the degenerative findings and 
clinical valve dysfunction is not always clear. Important factors contributing to 
valve failure are donor procurement, preservation methods and surgical 
techniques, The antigenicity of valve allografts has been frequently reported 
in animal studies""1O, In previous studies we showed the immunogenicity of 
fresh and cryopreserved valves in vitro" and in vivo12 , Hogan et al showed 
that cryopreserved human aortic valve allografts were able to elicit an donor-
specific antibody response against HLA-antigens14 , They also detected a 
significant increase in the proliferative response of recipient lymphocytes 
after stimulation with donor mononuclear cells on day 30 after implantation, 
We were able to confirm their data in a longitudinal study in patients who 
received a cryopreserved allograft, demonstrating antibodies directed against 
donor HLA class I and class II in peripheral blood15,16, These results of 
immune reactivity against transplantation antigens after implantation of a 
cryopreserved valve allograft suggest the presence of viable cells in the graft 
capable of expressing H LA class I and II antigens, The presence of H LA 
class I and class II positive cells have already been described by Yacoub et 
al in fresh human aortic allografts 17, 
In the present study we examined human valves for the distribution of 
various cell types, including antigen-presenting dendritic cells, which are 
involved in the initiation of the allogeneic response, Bobryshev et al 
described the presence of dendritic cells in the arterial intima and in 
atherosclerotic lesions 18, These dendritic cells are generally seen as the 
most potent antigen presenting cells, The presence and activation status of 
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endothelial cells on the surface and within the valve allograft was also 
investigated. Endothelial cells have the capacity to express HLA class II and 
other activation markers or adhesion molecules, making prime targets for 
immune reactions. However, they may also have antigen presenting 
capacities and thus are able to function as initiators of the immune 
response,g. 
Because processing steps like antibiotic sterilization and the 
cryopreservation procedure might influence the cellular composition, we 
compared fresh and cryopreserved pieces of leaflets and vascular wall of the 
same valve allograft. 
Material and methods 
Valve allografts. 
Two aortic and two pulmonary valves were studied derived from 3 donors, 
two heart beating and one non-heart beating donor. From each valve, one 
leaflet and the connecting piece of vascular wall were fixed in 4% form-
aldehyde. The remaining two leaflets and vessel roots were sterilized for 24 
hours at 4°e in Medium 199(Bio-Whiltaker, Alkmaar, The Netherlands) 
containing a low concentration antibiotic solution: vancomycin 0.012 mg/ml, 
flucytosin 0.03 mg/ml, amikacin 0.012 mg/ml, ciprofloxacin 0.003 mg/ml and 
metrenidazol 0.012 mg/ml. Thereafter they were cryopreserved (_iDe per 
minute) in Medium 199 containing 10% dimethyl sulfoxide (OMSO)2o and 
stored in the vapour phase of liquid nitrogen (-160 to -180°C) at the Heart 
Valve Bank in Rotterdam, The Netherlands. After 4 to 8 days the valves 
were thawed in a 37°e water-bath and the OM SO was removed by stepwise 
dilution in Medium 199. Immediately after this standard procedure the valves 
were fixed in 4% formaldehyde. To optimize antigen preservation the 
specimens were fixed for a maximum of 36 hours without decalcification. 
The samples were further processed by standard formalin fixation and 
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paraffin embedding procedures. 
ABC immunoperoxidase procedure. 
After embedding, 4pm sections were cut. The thin sections were 
deparaffinized and the endogenous peroxidase was blocked. If necessary 
antigens were retrieved by enzymatic digestion or microwave treatment. For 
enzymatic digestion the sections were treated with 0.1 % pronase in 
phosphate buffered saline (PBS) at 37°e for 10 minutes. To stop enzymatic 
treatment the sections were washed in PBS at 4°e for 10 minutes. For the 
microwave treatment 10mM citric acid buffer(pH 6,0) was warmed till 100oe. 
The sections were placed in the pre-heated citric acid and placed in the 
microwave and were treated at 1000e for 10 min. Thereafter the sections 
were cooled until room temperature was reached. Subsequently they were 
washed with H,O. After these procedures all the sections were washed in 
PBS. The non-specific binding was inhibited by incubation with 10% normal 
goat serum (DAKO, Glostrup, Denmark) in PBS with 5% bovine serum 
albumin (PBS/BSA) for 15 min. Thereafter, the sections were incubated with 
the specific antibodies listed in table 1, for 30 min or overnight at 4°e for the 
sections of which the antigens were retrieved by microwave heating. Anti-
bodies were diluted in PBS/BSA, in previously determined optimum 
concentration. After two times washing in PBS with 0.1 % Tween 20, the 
sections were incubated for 30 min with 2% biotin-labelled multilink 
secondary antibody (Biogenex, San Ramon, eA) with 2% normal human 
serum and 2% normal goat serum. Then the sections were washed two 
times with PBS/Tween and the 2% avidin labelled peroxidase complex 
(Biogenex) was added and incubated for 30 min. After washing with PBS, 
final staining was performed by 7 min treatment with 3,3-diaminobenzidine 
(DAB) and H,O" resulting in a brown precipitation. The sections were 
counterstained with Macer's haematoxylin. All the incubations were 
performed at room temperature unless otherwise noted. A multi-section was 
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used as positive control and for negative control sections were stained 
omitting the specific antibodies. 
Table 1. Monoe/onal antibodies used for Immunohistochemical staining. 
Monoclonal antibody 
JC70A 
1H4# 
KP1 
L26 
123C3.D5# 
CD3 (polyclonal) 
S-100 (polyclonal) 
CR3/43 
2B11 
Main specificity 
CD31 endothelial cells 
CD54 (ICAM 1) 
CD68 macrophages 
CD20 B-Iymphocytes 
CD56 (NCAM 1) HK cells, 
neuroectodermal cells 
T-Iymphocytes 
Dendritic celis, Schwann cells 
and melanocytes 
HLA-DP, -DQ, -DR 
CD45 Leucocyte Common Antigen 
# by Neomarkers, Fremont, USA. All others by DAKO, Glostrup, Denmark. 
Double staining procedure. To demonstrate that cells positive stained by 
S-100 were antigen presenting dendritic cells, a double staining with CD45 
was performed. In short, sections were deparaffinized and the endogenous 
peroxidase was blocked with H,02' After washing in H20 and PBS, the non-
specific staining was inhibited by incubation with 10% normal goat serum 
(DAKO) in PBS/BSA. Thereafter the sections were incubated for 30 min, with 
specific antibody direct against CD45. After washing with PBS/Tween, the 
sections were incubated for 30 min with 2% biotin-labelled multilink 
secondary antibody (Biogenex) with 2% human serum and 2% normal goat 
serum. Sections were washed with PBS/Tween, followed by 30 min 
incubation with 2% alkaline phosphatase labelled avidin complex (Biogenex) 
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in PBS/BSA. After washing in PBS and 0.05M Tris-buffer (pH 8.0), the colour 
detection was done with Fast Blue, resulting in blue stained CD45 positive 
cells. Hereafter, the sections were washed in Tris-buffer and PBS and 
incubated for 15 min with 10% normal swine serum (DAKO) in PBS/BSA for 
preventing non-specific binding. Subsequently, the sections were incubated 
for 30 min with specific S-100 antibody, followed by two washes with PBS. 
Sections were incubated for 30 min with 2% swine-anti-rabbit (DAKO) in 
PBS/BSA, rinsed twice with PBS and followed by an incubation step with 2% 
rabbit peroxidase-anti-peroxidase (PAP) complex (DAKO) in PBS/BSA for 30 
min. After this, the sections were washed in PBS and 0.02 M acetate buffer 
(pH 4.6) with 0.05% Tween 20 for 30 min, respectively. Staining was 
detected with 3-amino-9-ethylcarbozole (AEC) and H,O" followed by 
washing for 30 min in acetate buffer. As result all S-100 positive cells 
stained red. Double stained cells CD45 and S100 positive cells would be 
have a purple/brown staining. All incubations steps were performed at room 
temperature. 
Results 
In all positive control sections, staining was detected even when staining in 
the valves could not be demonstrated. In all negative sections of which the 
primary antibody was omitted, no staining was observed. 
No difference could be found in the intensity or distribution of the labelled 
cells when fresh valve leaflets were compared with the cryopreserved valve 
leaflets from the same valve allograft. 
Both fresh and cryopreserved leaflets were hardly covered with CD31 
positive endothelial cells, which are normally present on the valvular and 
vascular wall surfaces. Only in grooves of the cusp where the surface had a 
ruffled appearance, some CD31 positive endothelial cells were detected. 
Many CD31 positive endothelial cells were found in the vasa vasorum of the 
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tunica adventitia, the outer layer of vascular wall. These C031 positive 
endothelial cells all expressed HLA class II and the adhesion molecule C054 
(ICAM-1 )(figures 1A, 1 Band 1 C, suppementary sheet). 
C068 positive macrophages were present scattered throughout the leaflet 
and the vascular wall. Furthermore, some C068 positive macrophages were 
present around the vasa vasorum in the tunica adventitia. 
C020 positive B-Iymphocytes could not be detected neither in fresh nor in 
cryopreserved valves. 
A few C056 positive NK cells were present in 2 out of 4 valves examined. 
These C056 positive cells were located in the cusp on the ventricular 
surface and around the vasa vasorum in the tunica adventitia. 
All valve allografts showed groups of C03 positive T-Iymphocytes on the 
ventricular side of the valve cusp and in the tunica intima (fig 2A, 
supplementary sheet). C03 positive T-Iymphocytes were also present in the 
adventitia around the vasa vasorum. 
S-100 positive cells were present in large quantities within the leaflets of all 
valves tested. When these cells were double stained for C045 (Common 
Leucocyte Antigen), none of these cells showed a double staining for both of 
this antibodies (figures 2B and 2C, supplementary sheet). Most of the C045 
positive cells were seen at the ventricular side of the leaflets, while S-100 
positive cells were mainly found in the central layer of the valve leaflets. 
HLA class II positivity was seen in the ventricular side of the valve cusps, on 
morphological grounds probably on activated T-Iymphocytes. Also, forming a 
scattered pattern throughout the valve leaflets, other HLA class II cells were 
present. In the tunica intima and in the tunica adventitia cells positive for 
HLA class II were also seen. The last two staining patterns showed similarity 
with the C068 staining. Finally, the endothelial cells of the vasa vasorum 
were positive for HLA class II, demonstrating that these endothelial celis 
were activated (fig 1 B, supplementary sheet). 
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Figure 1. Immunohistochemical staining of cryopreserved human valve. A, CD31 staining 
of vasa vasorum in the tunica adventitia, showing the presence of endothelial cells. B f 
HLA class II staining of the vasa vasorum, demonstrating the presence of activated 
endothelial cells. C, C054 (/CAM-1) staining of the vasa vasorum, the arrows show the 
weak, though positive staining of CD54 positive activated endothelial cells , 
(All original magnifications 400x) 
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Figure 2. Immunohistochemical characterisation of immune-competent cells in 
cryopreselVed valves. A, CD3 staining in the leaflet of a valve allograft, demonstrating a 
group of T-Iymphocytes on the ventricular side of the leaflet, just below the absent 
endothelial lining. 
B, Staining with 8 -100 in the valve leaflet, showing the presence of an abundance of s-
100 positive celis, especially in the central area of the leaflets. C, Double staining for 
CD45 (in blue) and 8,100 (in red) in the valve leaflet, demonstrating only cells in red and 
blue and no double stained purple/brown cells. 
(Original magnification, A 200x, B 100x and C 400x) 
Discussion 
From earlier in vivo and in vitro studies it became clear that cardiac valve 
allografts are able to stimulate the immune system 8-16. In the present study, 
we have shown immunohistochemically that both fresh and cryopreserved 
valve allografts contain cells capable to express class II transplantation 
antigens. We also found that fresh valves did not show an endothelial cell 
lining on the valve surface. We showed that activated endothelial cells are 
abundantly present in the vasa vasorum of the vascular wall, expressing 
ICAM-1 and HLA class II. These cells may be involved in the initial phase of 
the immune response, either as target or as non-professional antigen 
presenting cells. 
Mononuclear cells from donor ongln were found in all valve specimens 
examined, especially groups of CD3 positive T-Iymphocytes in the ventricular 
side of the valve cusps and tunica adventitia. We did not test their viability in 
the present study, but our group earlier studied the survival of lymphocytes 
in cryopreserved endomyocardial biopsies of heart transplantation patients, 
and showed that T-Iymphocytes indeed could be cultured from 
cryopreserved tissue21 . 
In a morphologic study examining human valve allografts, Goffin and 
colleagues described the presence of 8-100 positive cells in valves before 
and after implantation". The authors reported that these cells were dendritic 
Langerhans cells. However, no double staining with CD45 or other controls 
were performed to ensure that these 8-100 positive cells were of leucocyte 
origin. It has indeed been described that human arterial valves are heavily 
innervated23. In the present study, double stained cells were not detected, 
while double stained cells were present in the control sections with lymphatic 
tissue. Therefore, these immunohistochemical results can not confirm the 
presence of these professional antigen presenting dendritic cells in fresh or 
cryopreserved valve allografts. Nevertheless, their presence can not be 
excluded because these cells are scarsely present. An alterative explanation 
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for initiating the immune response could be the activated non-professional 
APC, e.g. endothelial cells or even T-cells. 
In an experimental study by Mulligan et ai, the effect of preservation 
techniques on adhesion molecules was investigated24 • ICAM-1 was only 
detected in fresh valve allografts which were explanted after more than 28 
days. Cryopreserved valves and valves stored at 4°C did not express ICAM-
1 even after implantation. In the present study, ICAM-1 expression in the 
vasa vasorum was already present at the time of arrival at the Heart Valve 
Bank and did not disappear after the cryopreservation procedure. The 
activation of the endothelial cells and consequently expression of ICAM-1 
and HLA class II could have been initiated by non-specific activation caused 
by the brain death or perimortal stress of the donors. In a study with 
baboons, Novitzky et al demonstrated that in hearts after brain death, 
myocyte necrosis and mononuclear infiltrates are present25. This 
phenomenon could also be an explanation for the activated state of 
endothelium and presence of lymphocytes in the valves examined in this 
study. 
This immunohistochemical study may give an explanation for the immune 
response observed in vivo against valve allografts. The absence of a 
consistent amount of antigen presenting dendritic cells and the masked 
position of activated endothelial cells in the vasa vasorum in the valve 
allograft can be an explanation for the delay in the antibody response 
directed against HLA class II of the donor". On the other hand, the presence 
of activated endothelial cells, macrophages and lymphocytes of donor origin 
could also partially compensate for the lack of the donor antigen presenting 
dendritic cells. 
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Chapter 7 
SUMMARY AND CONCLUSIONS 
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Cardiac valve allografts have shown to be a good alternative for the 
replacement of semilunar heart valves in patients with acquired or congenital 
heart valve disease. The human aortic and pulmonary valve allografts have a 
superior hemodynamic performance, a relative resistance to endocarditis and 
a minimal amount of thromboembolic complications compared to porcine valve 
prostheses and mechanical valves. Moreover, patients with a valve allograft do 
not require anticoagulant therapy. Nevertheless, valve allograft degeneration 
is observed in allmost all explanted valves. These degenerative changes are 
partly caused by technical factors as surgical procedures and sizing. Further, 
valve insufficiency during the first year after implantation is frequently seen in 
young recipients. Because human cardiac valves are considered as grafts with 
a low antigenicity, they are transplanted without matching for ABO blood group 
antigens or Human Leucocyte Antigens (HLA) class I or class II between valve 
donor and recipient. Immunosuppressive drugs are also not routinely 
administered to valve recipients, in contrast to recipients of allogeneic organs 
or bone marrow. Therefore, an immunologic basis for valve degeneration, 
eventually leading to valve insufficiency is conceivable. In the present thesis we 
report our studies on the immunogenicity of fresh and cryopreserved human 
cardiac valves in vitro and in vivo. 
In chapter 1, various aspects of cardiac valve transplantation in animals and 
humans are reviewed. In the introduction of this chapter, storage techniques 
and criteria for donation of human donor valves are briefly mentioned. Then, 
the results of clinical follow-up studies after implantation of human donor valves 
are reported. Thereafter, the results of animal studies on antigeneic properties 
of valve allografts are described. In these animal studies sensitization of the 
recipients and signs of acute and chronic rejection are reported. Further, some 
aspects of the immunogenicity of human cardiac valves and of 
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immunomodulation and immunosuppression are mentioned. 
In chapter 2 the aim of this thesis is described. In short, because valve allograft 
degeneration in the clinic is frequently observed, we would like to evaluate the 
effects of human cardiac valves on immune-competent cells in vitro and in vivo. 
The results of the in vitro assays on the cellular immune response induced by 
human heart valve leaflets are reported in chapter 3. In a lymphocyte 
stimulation assay, both fresh and cryopreserved valve pieces stimulate the 
proliferation of lymphocytes mismatched for HLA -A, -8 and -DR with the valve 
donor. The proliferative response is lower when the responder lymphocytes are 
matched for HLA -DR with the valve donor, compared to responder cells which 
are mismatched for HLA -A, -8 and -DR. Cryopreserved valve pieces also 
induce a lower Iymphoproliferation compared to fresh valve pieces derived from 
the same valve allograft. Endothelial cells cultured from fresh valve leaflets 
induce higher Iymphoproliferative responses than cryopreserved valve pieces. 
In chapter 4 the presence of donor-specific cytotoxic T-Iymphocytes in 
explanted human cardiac valves is described. The majority of the valve 
allografts tested were explanted because of valve insufficiency. Lymphocyte 
cultures could be generated in 517 cases after incubation in an Interleukin-2 
containing culture medium, which selects only the in vivo activated 
lymphocytes. Phenotyping showed that T-cell receptors were present on 95% 
of the lymphocytes in each culture obtained. In a cell-mediated Iympholysis 
assay, donor-specific cytotoxicity against HLA class I and/or class II antigens 
was detected in 3 patients of which the HLA-type of the valve donor was 
available. 
The results of the detection of antibodies against HLA class I and class II in 
patients with a cryopreserved valve allograft are described in chapter 5. Panel 
Reactive Antibodies (PRA) were present in the majority of the recipients (78%) 
between 1-16 months after valve implantation. In the control blood samples 
taken on the day of transplantation, antibodies could not be detected. In 21/32 
patients tested the HLA-type of the valve donor was available. In 14/17 patients 
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with a follow-up period of more than one month and of which the HLA-type of 
the valve donor was available, antibodies were present. Out of these 14 
patients, 12 patients showed anti-H LA class I antibodies specifically directed 
against the donor. Antibodies directed against HLA class II antigens were 
present in 37% of the recipients examined. In 82% these antibodies were 
donor-specific. Oithiothreitol (OTT) analysis showed that the antibodies were 
of the Immunoglobulin G (lgG) type. The induction of antibodies directed 
against HLA class II antigens requires the presentation of intact HLA class II 
moleCUles in the graft, which can only be expressed by viable cells. The 
induction of IgG antibodies also confirms the immunogeneic expression of HLA 
class II within the valve allograft, because activation of specific T-Helper cells 
is essential for the switch from IgM to IgG antibodies. 
The results of an immunohistochemical study on the cellular composition, the 
presence of endothelial cells and adhesion molecules and the expression of 
HLA -DR molecules in fresh and cryopreserved human valves are shown in 
chapter 6. The endothelial lining normally present on the surface of valve 
leaflet and vascular wall could not be detected, neither on fresh nor on 
cryopreserved valves. On the other hand, activated endothelial cells expressing 
adhesion molecules (ICAM-I) and HLA class II were present in the vasa 
vasorum of the tunica adventitia of fresh and cryopreserved aortic and 
pulmonary roots. The potent professional antigen-presenting dendritic cells 
could not be detected. Macrophages and lymphocytes were present in both 
fresh and cryopreserved valves, distributed in small groups throughout the 
graft. These results support the findings of previous chapters in this thesis, 
because activated endothelial cells, lymphocytes and macrophages of donor 
origin in the graft can potentially initiate a cellular and/or humoral immune 
response. Although immunohistochemical techniques are not developed to 
evaluate the viability of cells, we believe that living, activated donor cells are 
still present after valve transplantation. The masked position of endothelial cells 
and the absence of professional antigen-presenting cells could be an 
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explanation for the delay in the onset of the humoral immune response 
described in chapter 5. 
We conclude that cryopreserved human cardiac valves are not 
immunologically innocent as was earlier assumed by some authors. This is 
illustrated by the stimulation of immune-competent cells in vitro induced by 
human valve pieces, the presence of donor-specific cytotoxic T-Iymphocytes 
in explanted valve allografts, the production of antibodies specifically directed 
at donor antigens in the majority of the valve recipients and the 
immunohistochemically detected activated endothelial cells and other potential 
antigen-presenting cells. When these results are extended to the clinical 
setting, some recommandations could be done. First, to prevent hyperacute 
antibody-mediated rejections in sensitized recipients, we suggest 
crossmatching before valve implantation. Further, the HLA-type of valve donor 
and recipient should be available to study the long-term effect of 
immunohistincompatibility on graft survival. Up till now, recipients of valve 
allografts are not routinely HLA-typed. Matching for HLA class I and/or II 
between donor and recipient could be performed, although this may not be 
practicable because of the shortage of donor valves. In our opinion, the use of 
immunosuppressive drugs should be limited to high risk patients, but only for 
a short while and low-dose because complications of long-term 
immunosuppression may not outweigh its benefits. 
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SAMENVATTING EN CONCLUSIES 
Transplantatie is inmiddels een geaccepteerde methode om zieke weefsels of 
organen te vervangen. Menselijke donor-hartkleppen kunnen ge'implanteerd 
worden ter vervanging van niet goed functionerende aorta-en 
pulmonaalkleppen. De transplantaatoverleving van deze humane kleppen bij 
oudere ontvangers is vergelijkbaar met de overlevingsduur van mechanische 
klepprothesen. Verder hebben menselijke hartkleptransplantaten belangrijke 
voordelen vergeleken metvarkenskleppen en mechanische klepprothesen. Ten 
eerste is het niet noodzakelijk dat patienten met een humane donorhartklep 
behandeld worden met bloedverdunnende medicijnen. Ten tweede zijn het de 
enige kleppen die gebruikt kunnen worden ter vervanging van falende 
hartkleppen ten gevolge van acute endocarditis (ontsteking van de hartklep). 
Tenslotte kan met een humane hartklep een zo fysiologisch mogelijke 
uitstroombaan uit de ventrikel geconstrueerd worden en is het risico op 
thromboembolische complicaties bij de humane kleppen het laagst. 
Desalniettemin ontstaan er degeneratieve afwijkingen in klepslippen en de 
vaatwand in bijna aile kleptransplantaten op lange termijn na implantatie. 
Hoewel chirurgisch-technische factoren en verschillen in grootte van de 
getransplanteerde hartklep ten opzichte van de vaten van de klep-ontvanger 
ook kunnen leiden tot degeneratie van het getransplanteerde weefsel, kunnen 
hierdoor lang niet aile degeneratieve verschijnselen verklaard worden. Indien 
er bij explantatie geen duidelijke chirurgisch-technische oorzaak voor het 
kleptransplantaatfalen gevonden wordt, spreekt men van structureel klepfalen. 
Bij jonge kleptransplantaat-ontvangers wordt frequent klepfalen op korte termijn 
(binnen een jaar na implantatie) geconstateerd, waarvoor implantatie van een 
nieuwe donorklep noodzakelijk is. Omdat de humane hartkleppen beschouwd 
worden als transplantaten met een lage antigeniciteit, worden zij ge'implanteerd 
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zonder te matchen voor de transplantatie-antigenen, de "Human Leucocyte 
Antigens" (HLA) klasse I en II tussen klepdonor en klepontvanger. Tevens 
worden patienten met een humane donorhartklep niet routinematig behandeld 
met immunosuppressiva, zoals dit wei standaard plaatsvindt bij ontvangers van 
allogeen beenmerg of een orgaantransplantaat (nier, hart, lever). Een 
immunologische oorzaak voor de in de kleptransplantaten gevonden 
degeneratieve afwijkingen is daarom niet ondenkbaar. In dit proefschrift worden 
de resultaten beschreven enkele studies over de immunogeniciteit van verse 
en gecryopreserveerde menselijke donorhartkleppen. 
In hoofdsfuk 1 worden verschillende aspecten van hartkleptransplantatie bij 
dieren en mensen samengevat, die bekend waren in de literatuur voordat aan 
het onderzoek beschreven in dit proefschrift werd begonnen. In de introductie 
van hoofdstuk 1 worden de verschillende opslagtechnieken van humane 
donorhartkleppen beschreven. Vervolgens worden de resultaten genoemd van 
klinische follow-up studies met betrekking tot de transplantaatoverleving. 
Daarna voigt een overzicht van de resultaten van onderzoek gericht op de 
antigeniciteit van hartkleptransplantaten bij dieren. Hieruit blijkt dat hartkleppen 
in staat zijn tot sensibilisatie van de ontvangers. In de klepslippen werden 
tekenen gevonden van chronische en acute afstoting. Vervolgens worden 
enkele aspecten genoemd van het reeds verrichte beperkte onderzoek naar de 
immunogeniciteit van humane donorkleppen. Tenslotte worden enkele vormen 
van immunomodulatie en immunosuppressie genoemd. 
In hoofdsfuk 2 wordt het doe I van dit proefschrift beschreven. Kort samengevat 
worden enkele immunologische fenomenen in vitro en in vivo getoond die op 
kunnen treden na implantatie van allogeen weefsel, met als doel het in de 
kliniek vaak voorkomende structurele kleptransplantaatfalen te kunnen 
verklaren. 
De resultaten van in vitro onderzoek gericht op de cellulaire immuunrespons 
van humane hartkleppen worden getoond in hoofdsfuk 3. Verse en 
gecryopreserveerde stukjes hartklep worden getest op hun capaciteit am 
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Iymfocyten te stimuleren tot proliferatie in een Iymfocyten stimulatie test. Zowel 
verse als gecryopreserveerde klepstukjes zijn in deze test in staat tot stimulatie 
van de Iymfoproliferatie, wanneer de Iymfocyten gemismatched zijn met de 
klepdonor voor HLA -A, -8 en -DR. Deze proliferatieve respons is lager 
wanneer de Iymfocyten gematched worden voor HLA -DR met de klepdonor. 
Gecryopreserveerde klepstukjes geven ook een lagere stimulatie van de 
Iymfoproliferatie vergeleken met verse klepstukjes van helzelfde transplantaal. 
Endotheelcellen kunnen gemakkelijk gersoleerd en gekweekt worden van verse 
hartklepslippen. Deze cell en zijn in staat tot een hogere stimulatie van de 
Iymfoproliferatie dan gecryopreserveerde hartklepstukjes. Endolheel vormt de 
eersle barriere tussen donor- en acceptorcellen en zou hierom een rol kunnen 
spelen bij de initiatie van de immuunrespons. 
In hoofdsluk 4 wordt de aanwezigheid van donor-specifieke T-Iymfocyten in 
geexplanteerde kleptansplantaten beschreven. Van zeven onderzochte 
explanlaten werden er vijf verwijderd vanwege klep-insufficienlie. Door kleine 
stukjes geexplanteerde hartklep te incuberen in een kweekmedium met 
Interleukine 2, kunnen in vivo geacliveerde Iymfocyten prolifereren, zodat 
Iymfocytenkweken ontstaan. Uit vijf van de zeven explantaten werden 
Iymfocytenkweken verkregen, die elk uit meer dan 95% T-Iymfocyten bleken 
te bestaan. Drie van deze kweken, waarvan tevens de HLA-Iypering van de 
donor bekend was, bezaten donor-specifieke cytotoxiciteit tegen HLA klasse 
I en/of II, getest in een "cell-mediated Iympholysis assay". 
De resultaten van de bepalingen van antilichamen bij patienten mel een 
gecryopreserveerd hartkleptransplantaat worden vermeld in hoofdsluk 5. Panel 
Reactive Antibodies (PRA) werden gedetecteerd bij 78% van de onderzochte 
patienten tussen een en zestien maanden na implanlatie. In de controlegroep, 
waarbij bloedmonsters afgenomen werden op de dag van transplantatie, 
konden geen antilichamen aangetoond worden. De HLA-typering van de 
hartklepdonor was bekend van 21 van de 32 onderzochte patienten. De follow-
up peri ode was in 17 van deze 21 gevallen langer dan een maand. Veertien 
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van deze 17 patienten hadden antilichamen gericht tegen HLA klasse I, 
waarvan de antichamen bij 12 patienten specifiek gericht waren tegen HLA 
klasse I van de donor. 37% van de patienten bezaten antilichamen tegen HLA 
klasse II, waarvan 82% donor-specifiek was. Verder liet analyse met 
Dithiothreitol (DTT) zien dat de gevormde antilichamen behoorden tot de 
Immunoglobuline G (lgG) klasse. Het feit dat er bij hartkleptransplantatie 
antilichamen gevormd worden tegen HLA klasse II, suggereert dat er in het 
transplantaat levende cell en aanwezig zijn, die inlacte HLA klasse II molekulen 
tot expressie brengen. De vorming van IgG antilichamen bevestigt dat intacte 
HLA klasse II antigen en lot expressie gebracht worden, omdat v~~r de switch 
in antilichaamproduclie van IgM naar IgG activalie van specifieke T-Helper 
cellen essenlieel is. 
In hoofdstuk 6 worden de resultaten weergegeven van immunohistochemisch 
onderzoek gericht op de aanwezigheid van antigeenpresenterende cellen, 
endotheelcellen met eventuele adhesiemolekulen en de expressie van HLA-DR 
in verse en gecryopreserveerde humane hartkleppen. Endotheelcellen waren 
nauwelijks aanwezig aan de oppervlakte van de klepslippen of vaatwand bij 
zowel verse als gecryopreserveerde allografts. Echter, in de vasa vasorum van 
de adventitia van verse en gecryopreserveerde kleppen waren wei veel 
endolheelcellen aanwezig, die bovendien adhesiemolekulen (ICAM-I) en HLA-
DR tot expressie brachten. Dendritische cellen (potente professionele antigeen 
presenlerende cell en) werden met deze techniek niet gevonden. Vanwege de 
lage frequentie waarin deze cellen voorkomen kan er echter sprake zijn van 
een sampling-error. Verder werden enkele macrofagen gezien en tevens 
groepjes Iymfocyten, verspreid in hel transplantaat. Deze resultaten 
ondersteunen de bevindingen vermeld in voorgaande hoofdslukken, omdat de 
donor HLA klasse II antigenen, Iymfocyten, macrofagen 
endotheelcellen in he! transplan!aa! een humorale 
en geactiveerde 
en/of cellulaire 
immuunrespons tegen de donor op gang zouden kunnen brengen. Hoewel de 
immunohistochemische techniek geen informalie geeft over de 
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levensva!baarheid van de in he! transplantaat aanwezige cellen, denken wij 
toch dat levende cellen van donor origine aanwezig zijn tijdens en na de 
implantatie procedure. Oat de antilichaamrespons later optreedt dan verwacht, 
zou verklaard kunnen worden door het feit dat de immunogene donorcellen niet 
direct in contact kunnen komen met immuuncompetente cell en van de 
acceptor, zoals het endotheel dat "gemaskeerd" is vanwege het voorkomen in 
de kleine vaatjes van de adventitia. 
Wij conciuderen dat humane hartkleppen immunologisch niet onschuldig zijn, 
zoals in het verleden door meerdere auteurs werd beweerd. Oit wordt 
ge'lilustreerd door de in dit proefschrift beschreven stimulatie van 
immuuncompetente cellen in vitro in de aanwezigheid van verse of 
gecryopreserveerde klepstukjes, de aanwezigheid van specifiek tegen de donor 
gerichte antilichamen en cytotoxische T-cellen in geexplanteerde 
kleptransplantaten en de door immunohistochemische kleuringen aangetoonde 
geactiveerde endotheelcellen en andere niet professionele antigeen-
presenterende cellen. Naar aanleiding van bovengenoemde bevindingen 
zouden enkele aanbevelingen gedaan kunnen worden voor toekomstige 
hartkleptransplantaties. Om acute, antilichaam-gemedieerde afstotingen bij 
gesensibiliseerde patienten te voorkomen adviseren wij om v~~r implantatie 
van een donorhartklep kruisproeven te verrichten. Verder zou de HLA-typering 
van zowel klepdonor als klepontvanger bekend moeten zijn, om het effect van 
histo'lncompatibiliteit op de klinische functie van de hartklep op lange termijn 
te kunnen bestuderen (tot op heden wordt de HLA-typering van de hartklep-
acceptor namelijk niet routinematig bepaald). Vanwege het gunstige effect van 
HLA -DR matching op de stimulatie van de Iymfoproliferatie in vitro, is in de 
kliniek mogelijk ook een gunstig effect op de transplantaatoverleving te 
verwachten. Waarschijnlijk is het match en voor HLA klasse I en/of II antigenen 
in de kliniek momenteel echter niet haalbaar vanwege het tekort aan donoren. 
De toediening van immunosuppressiva in lage dosis en voor een beperkte tijd 
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zou beperk! moeten blijven tot de groep patienten met een hoog risico op 
!ransplantaatfalen, omda! de bijwerkingen van deze !herapie op de lange 
termijn waarschijnlijk nie! opwegen !egen de voordelen. 
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DANKWOORD 
In sommige opzichten is het tot stand komen van een proefschrift een grotere 
bevalling dan de geboorte van een kind. Vele personen hebben sinds het 
opstarten van het onderzoek in 1993 een belangrijke bijdrage geleverd. 
Ten eerste wil ik mijn promotor, Willem Weimar in he! bijzonder bedanken. Het 
begon allemaal tijdens het keuze-coschap nefrologie, toen je mij aan een baan 
hielp: arts-onderzoeker op het Transplantatie Laboratorium Interne I. Ik heb 
veel van je geleerd op uiteenlopende gebieden, onder meer: artikelen schrijven, 
statistiek bedrijven (bij n<11) en het houden van voordrachten. Onvergetelijk 
is ook het bezoek aan "Webster Hall" tijdens het ISHL T-congres in 1996 in 
New York. Je kritische, relativerende en vaak cynische opmerkingen waren 
onontbeerlijk voor de bereikte resultaten en blijven noodzakelijk voor de 
voortgang van het hartkleppenonderzoek. 
Vervolgens bedank ik de leden van de promotie commissie voor het 
doornemen van het manuscript. Frans Claas, veel dank voor de mogelijkheid 
om de antilichaambepalingen in Leiden te laten verrichten, de opbouwende 
kritiek en adviezen bij de voorbereiding van meerdere artikelen. 
Prof. Dr. MAD.H. Schalekamp en Dr. A.G.C. Bauer wil ik bedanken voor het 
feit dat ik gedurende mijn AGNIO- en AGIO-periode de tijd kreeg voor het 
verrichten van onderzoek, het bezoeken van congressen en het schrijven van 
artikelen. 
Een groot deel van de studie werd uitgevoerd in een goede werksfeer op het 
Lab Interne I. Chris, zonder jouw speciale aandacht was er van dit onderzoek 
weinig terecht gekomen. Meerdere laboratoriumtechnieken heb je mij met vee I 
geduld in korte tijd bijgebracht. De meeste hartklepstukjes gebruikt voor de 
MLR had ik zonder jouw hulp nooit teruggevonden. Nicole, Nancy, Len, Lisette, 
Paula, Sjors/George, Nicolet, Wendy, Cecile, Rene, Barbara, Cees, Ronella, 
Hester, Frans, Marij, dank v~~r jullie steun en gezelligheid. Nicolet, bedankt 
v~~r het openen van mijn belangrijke post. Carla dank ik voor haar geduld en 
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hulp bij mijn problemen met de computer. George, ik bewonder je 
vasthoudendheid wat betreft het verkrijgen van bloedmonsters. 
Zonder de levering van voor transplantatie afgekeurde hartkleppen van de 
rotterdamse hartkleppenbank had het onderzoek niet plaats kunnen vinden. 
Corina, Zohara en Claas: bedankt voor jullie hulp en adviezen. 
Marian Witvliet, via jou wil ik graag iedereen bedanken op de afdeling 
Immunohematologie en Bloed Bank in Leiden die aan de antilichaambepalingen 
hebben meegewerkt. 
Van mijn twee paranymfen was het Rob Klaassen die van van tijd tot tijd 
ge"lnteresseerd informeerde hoe het met de voortgang het kleppenonderzoek 
ging. Ginette Carels toonde frequent haar steun als collega in het 
Havenziekenhuis. 
Marco, zonder jouw kennis van computers had de totstandkoming van dit 
proefschrift nog veellanger geduurd! Tenslotte: Roos: het grootste deel van het 
voorbereidende werk voor het proefschrift was gelukkig klaar voordat jij 
geboren werd. Onvergetelijk is wei het moment dat je op het bureau van 
Professor Claas poe pte toen we het manuscript gingen overhandigen. 
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CURRICULUM VITAE 
De auteur van dit proefschrift werd geboren op 31 maart 1968 in Rotterdam. 
In 1986 behaalde zij het Atheneum-B diploma aan het Jacob Roelandslyceum 
te Boxtel. Zij startte in hetzelfde jaar met de studie Geneeskunde aan de 
Erasmus Universiteit te Rotterdam, waar in 1993 het artsexamen werd 
verkregen (cum laude). Aansluitend werd begonnen met het in dit proefschrift 
beschreven onderzoek op het Transplantatie Laboratorium Interne I (Prof. Dr. 
W. Weimar), Academisch Ziekenhuis Rotterdam (AZR). In augustus 1994 werd 
op het VI International Symposium On Cardiac Bioprostheses in Vancouver, 
Canada, de Carpentier-Edwards Basic Research Award verkregen voor de 
voordracht over de immunogeniciteit van humane hartkleppen in vitro. Vanaf 
januari 1994 was zij werkzaam als arts-assistent niet in opleiding op de 
afdeling Interne I (Prof. Dr. MAD.H. Schalekamp) in het AZR. Aansluitend 
begon zij op 1 januari 1996 aan de opleiding tot internist in het 
Havenziekenhuis te Rotterdam (opleider: Dr. A.G.C. Bauer). Momenteel is zij 
werkzaam als arts-assistent op de afdeling Interne Geneeskunde I om de 
opleiding te voltooien. 
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